



Medicines & Healthcare products  
Regulatory Agency

**Contract**  
**Sterility Testing services**  
**Medicines & Healthcare products Regulatory Agency**  
**C323336**

**SHORT FORM CONTRACT FOR THE SUPPLY OF GOODS AND/OR SERVICES**

Medicines and Healthcare products Regulatory Agency  
10 South Colonnade,  
Canary Wharf, London  
E14 4PU

Reading Scientific Services Limited,  
The Reading Science Centre,  
Whiteknights Campus,  
Pepper Lane,  
Reading,  
RG6 6LA,  
United Kingdom

Date: 28.05.2025  
Our ref: C323336

Dear Sir/ Madam,

Following the end of Evaluation for the contract for **Sterility Testing services to Medicines and Healthcare products Regulatory Agency (MHRA)** we are pleased to confirm our intention to award this Contract to you.

The attached Order Form, contract Conditions and the Annexes set out the terms of the Contract between (MHRA) and Reading Scientific Services Limited for the provision of the Deliverables set out in the Order Form.

Please confirm your acceptance of this Contract by signing and returning it (via Atamis e-tendering portal) within seven (7) days from the date of the Order Form. No other form of acknowledgement will be accepted. Please remember to include the reference number(s) above in any future communications relating to this Contract.

We will then arrange for the Order Form to be countersigned and returned.



Medicines & Healthcare products  
Regulatory Agency

Yours faithfully,

[Redacted signature]



## Medicines & Healthcare products Regulatory Agency

### Order Form

<b>1. Contract Reference</b>	C323336	
<b>2. Buyer</b>	Medicines and Healthcare products Regulatory Agency 10 South Colonnade, Canary Wharf, London E14 4PU	
<b>3. Supplier</b>	Reading Scientific Services Limited, The Reading Science Centre, Whiteknights Campus, Pepper Lane, Reading, RG6 6LA, United Kingdom	
<b>4. The Contract</b>	<p>This Contract between the Buyer and the Supplier is for the supply of Deliverables.</p> <p>The Supplier shall supply the Deliverables described below on the terms set out in this Order Form and the attached contract conditions ("<b>Conditions</b>") and the Annexes.</p> <p>Unless the context otherwise requires, capitalised expressions used in this Order Form have the same meanings as in the Conditions.</p> <p>In the event of any conflict between this Order Form and the Conditions, this Order Form shall prevail.</p>	
<b>5. Deliverables</b>	<b>Services</b>	<p>Sterility Testing services, as set out in Annex 2 – Specification (C323336).</p> <p>To be performed at MHRA South Mimms, Blanche Lane, South Mimms, Potters Bar, Herts, EN6 3QG</p>
<b>6. Specification</b>	The specification of the Deliverables is as set out in Annex 2 – Specification (C323336).	
<b>7. Start Date</b>	Contract Start Date: 02 <sup>nd</sup> of June 2025	
<b>8. Expiry Date</b>	Contract End Date: 02 <sup>nd</sup> of June 2028	
<b>9. Extension Period</b>	The Conditions of the Contract shall apply throughout any such extended period. The Buyer may extend the Contract for a maximum 12 months on up to <u>two</u> occasions on giving not less than 60 days' notice ( <b>Extension Notice</b> ), provided that the Term of the Contract	



## Medicines & Healthcare products Regulatory Agency

	<p>shall not extend beyond 5 years from the Service Start Date. Where the Contract is extended, the Expiry Date shall be varied to accommodate the extended Term of the Contract.</p> <p>The Supplier shall, within 5 Working Days (or a period as otherwise agreed between the Parties) of receipt of the Extension Notice, notify the Buyer whether it agrees to such extension ("<b>Response Notice</b>"). If the Supplier does not agree to an extension, the Contract shall expire on the Expiry Date. If the Response Notice confirms the Supplier's agreement to the extension or if the Supplier does not respond within 5 Working Days (or the period as otherwise agreed between the Parties), the Contract shall be deemed extended in accordance with the terms of the Extension Notice and other than the Contract Period, all other terms of the Contract shall continue unaffected.</p>
<b>10. Optional Intellectual Property Rights ("IPR") Clauses</b>	As stated under clause 10
<b>11. Payment</b>	<p>Payment of undisputed invoices will be made within 30 days of receipt of invoice, which must be submitted promptly by the Supplier.</p> <p>All invoices must be accurate and submitted monthly to: [REDACTED]</p> <p>The Supplier must be in receipt of a valid PO Number before submitting an invoice.</p> <p>Invoices should be separated into one price line per collection and must be detailed so that each invoice can be matched to each collection document. To avoid delay in payment, the invoice must be compliant and must include as a minimum:</p> <ol style="list-style-type: none"><li>1. a valid Purchase Order Number;</li><li>2. item number (if applicable) or service to which the invoice relates;</li><li>3. the details (name, email, and telephone number) of the Buyer contact (i.e. Buyer Authorised Representative)</li><li>4. date of collection; and</li><li>5. which bins were collected.</li></ol> <p>Non-compliant invoices, invoices which do not include the minimum amount of information required above, invoices that cannot be matched to a collection document, or which do not have a relevant purchase order number quoted will be sent back to the Supplier to be properly completed, which may lead to a delay in payment.</p>



## Medicines & Healthcare products Regulatory Agency

	<p>If the Supplier has a query regarding an outstanding payment it should contact the Buyer's Accounts Payable team either by email to: [REDACTED]</p> <p>The Buyer uses Oracle Fusion as the Procure to Pay system. The Supplier must register on Oracle Fusion so that the Supplier can:</p> <ol style="list-style-type: none"><li>6. Add and amend sales and accounts receivable addresses.</li><li>7. Add or amend contacts / representatives.</li><li>8. Add or amend payment details.</li></ol> <p>Failure by the Supplier to register on Oracle Fusion will result in the Buyer being unable to pay invoices. Notwithstanding any other provision in this Contract, the Buyer shall in no circumstances be liable to the Supplier for any delay in payment due to a failure by the Supplier to register with Oracle Fusion.</p> <p>The Supplier must not supply the Buyer with any goods or services until the Supplier is in receipt of a valid Purchase Order from the Buyer. Supplying goods or services to the Buyer without a valid Purchase Order may result in the Buyer being unable to pay the relevant invoices.</p>
<b>12. Data Protection Liability Cap</b>	<p><del>In accordance with clause 12.5 of the Conditions, the Supplier's total aggregate liability under clause 14.7(e) of the Conditions is no more than the Data Protection Liability Cap, being £500,000.</del></p>
<b>13. Progress Meetings and Progress Reports</b>	<p>As mentioned in the Technical Envelope (C323336)</p>
<b>14. Buyer Authorised Representative(s)</b>	<p>For Contract and Site related queries your contact will continue to be:</p> <p>[REDACTED]</p> <p>or, in their absence,</p> <p>[REDACTED]</p> <p>For payment queries, your contact will be:</p> <p>Accounts Payable:</p>



## Medicines & Healthcare products Regulatory Agency

<b>15. Supplier Authorised Representative(s)</b>	For general liaison your contact will continue to be:  [REDACTED]  or, in their absence,  [REDACTED]	
<b>16. Address for notices</b>	<b>Buyer:</b> FAO: [REDACTED]  MHRA, Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG, United Kingdom	<b>Supplier:</b> FAO: [REDACTED]  Reading Scientific Services Limited, The Reading Science Centre, Whiteknights Campus, Pepper Lane, Reading, RG6 6LA, United Kingdom
<b>17. Key Supplier Staff</b>	[REDACTED]	
<b>18. Procedures and Policies</b>	<p>For the purposes of the Contract the:</p> <p><del>Contractors must undergo and pass any security checks deemed necessary by NIBSC. Failure to do so could result in access to NIBSC being denied. It is the service provider's responsibility to ensure service engineers progress the security clearance in a timely manner when required and are mindful of new engineers who may attend site, and try and pre-empt the process, with a request for security clearance prior to them attending site.</del></p>	
<b>19. Special Terms</b>	<p>1. <b>Liability Cap:</b> Clause 12.1 of the Conditions is deleted and replaced with the following:</p> <p>Each Party's total aggregate liability under or in connection with the Contract (whether in tort, contract or otherwise) is no more than 125% of the Charges paid or payable to the Supplier.</p>	





## Medicines & Healthcare products Regulatory Agency

	<p>2. <b>Modern Slavery:</b> A new clause is inserted into clause 13 of the Conditions (Obeying the law):</p> <p>The Supplier shall comply with any request by the Buyer to complete the Modern Slavery Assessment Tool, which can be found online at: <a href="https://supplierregistration.cabinetoffice.gov.uk/msat">https://supplierregistration.cabinetoffice.gov.uk/msat</a>, within sixty (60) days of such request. Guidance attached to <a href="#">PPN 05/19 (Modern Slavery)</a>.</p>
<b>20. Incorporated Terms</b>	<p>The following documents are incorporated into the Contract. If there is any conflict, the following descending order of precedence applies:</p> <ul style="list-style-type: none"><li>a) This Order Form</li><li>b) Any Special Terms [see row 19 (Special Terms) in this Order Form]</li><li>c) Conditions (as they may be amended by</li><li>d) The following Annexes in equal order of precedence:<ul style="list-style-type: none"><li>Annex 1 – Processing Personal Data</li><li>Annex 2 – Specification</li><li>Annex 3 – Charges</li><li>Annex 4 – Clarifications</li><li>Annex 5 – TPA (Third Party Agreement)</li></ul></li></ul>

Signed for and on behalf of the <b>Supplier</b> <u>Reading Scientific Services Limited</u>	Signed for and on behalf of the <b>Buyer</b> <u>Medicines and Healthcare products Regulatory Agency</u>
Name: [REDACTED]	Name: [REDACTED]
Title: [REDACTED]	Title: [REDACTED]
Date: 04.06.2025	Date: 06.06.2025



Medicines & Healthcare products  
Regulatory Agency

Signature: 	Signature: 

**Where appropriate, this Order Form may be signed electronically by both Parties**





# Medicines & Healthcare products Regulatory Agency

## Annex 1 – Processing Personal Data

### A. Part A - Authorised Processing Template

<b>Contract:</b>	<b>C323336</b>
<b>Date:</b>	28.05.2025
<b>Description of authorised processing</b>	Details
Identity of Controller and Processor for each category of Personal Data	No Personal Data will be processed.
Subject matter of the processing	MHRA staff work contract details will be held by the supplier.
Duration of the processing	The life of the contract.
Nature and purposes of the processing	N/A
Type of Personal Data	Work contract details.
Categories of Data Subject	MHRA staff including temporary staff.
Plan for return and destruction of the data once the processing is complete UNLESS requirement under law to preserve that type of data	N/A
Locations at which the Supplier and/or its Subcontractors process Personal Data under this Contract	Any in UK
Protective Measures that the Supplier and, where applicable, its Subcontractors have implemented to protect Personal Data processed under this Contract against a breach of security (insofar as that breach of security relates to data) or a Personal Data Breach	N/A




Medicines & Healthcare products  
Regulatory Agency

A. Part B – Joint Controller Agreement

**Not used**



**Annex 2 – Specification (Supplier response under Tender C323336)**





### **Annex 3 – Charges**

#### **1. How Charges are calculated**

- 1.1 The Charges shall be calculated in accordance with the terms of this Annex 3.
- 1.2 Any variation to the Charges must be agreed between the Supplier and the Buyer and implemented using the procedure set out in this Annex 3.

#### **2. The pricing mechanisms**


- 2.1 Appendix 1 to this Annex 3 sets out the Charges payable.
- 2.2 The Supplier shall be entitled to an increase in the Charges for year 3 of the Contract and any period(s) of extension to the Term agreed in accordance with the terms of this Contract and any such increase shall be calculated by reference to the index value of the CPI (In the UK) for the month that falls two months before the end of the Contract year immediately preceding the start of the Contract year for which the increase in Charges is being calculated.
- 2.3 Where the Consumer Price Index:
  - (a) used to carry out an indexation calculation is updated (for example due to it being provisional) then the indexation calculation shall also be updated unless the Buyer and the Supplier agree otherwise;
  - (b) is no longer published, the Buyer and the Supplier shall agree a fair and reasonable replacement that will have substantially the same effect.

#### **3. Costs and expenses included in the Charges**

- 3.1 The Charges shall include all costs and expenses relating to the provision of the Services. No further amounts shall be payable in respect of matters such as:
  - (a) incidental expenses such as travel, subsistence and lodging, document or report reproduction, shipping, desktop or office equipment costs, network or data interchange costs or other telecommunications charges; or
  - (b) costs incurred prior to the commencement of the Contract.



**Appendix 1 to Annex 3 – Charges applicable**





**Annex 4 – Clarifications (During Tender evaluation for C323336)**



Medicines & Healthcare products  
Regulatory Agency

**Annex 5 – TPA (Third Party Agreement)**



## Third-Party Agreement

**BETWEEN**

HTA Licensed Establishment (herein the “Customer”)	
HTA Licence Number	
Establishment Name	United Kingdom Stem Cell Bank, C/O Medicines and Healthcare products Regulatory Agency
Establishment Address	Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK
Designated Individual	Name: Email:
Individual responsible of this agreement	Name: Email: Job title:
Designated Contact(s)	Name: Email: Job title: Name: Email: Job title: Name: Email: Job title:

**AND**

Third-Party Establishment (herein the “Supplier”)	
Establishment name	Reading Scientific Services Ltd
Establishment address	Reading Scientific Services Limited, The Reading Science Centre, Whiteknights Campus, Pepper Lane, Reading, RG6 6LA,





## Medicines & Healthcare products Regulatory Agency

	United Kingdom	
Individual responsible of this agreement	Name [REDACTED]	Email [REDACTED]
	Job title:	
Designated Contact (s)	Name [REDACTED]	Email [REDACTED]
	Job title:	
	Name [REDACTED]	Email [REDACTED]
	Job title:	



## Medicines & Healthcare products Regulatory Agency

### Licensable Service

- ☐ Procurement
- ☒ Testing service that affects quality or safety
- ☐ Distribution
- ☐ Export
- ☐ Supply of goods that affect quality or safety
- ☐ Supply of service that affects quality or safety
- ☐ Calibration or maintenance service
- ☐ Other (please specify): Courier service for distribution of Materials

### Overview of the Service

UKSCB distribute and bank several cell products, including, but not limited to, human embryonic stem cell lines and human dermal fibroblasts. UKSCB require a GMP/ accredited Sterility Testing service prior to release for Human Application.

This licensable activity will be carried out by the Supplier on behalf of the Customer in accordance with Specifications and the Customer requirements.

### Third-Party Agreement Next Review

Individual  
coordinating the  
review

Name

Position



Medicines & Healthcare products  
Regulatory Agency

Email



Next review date



## Medicines & Healthcare products Regulatory Agency

### Glossary and definitions

<b>Cell</b>	Individual human cells or a collection of human cells when not bound by any form of connective tissue, including cell lines grown outside the human body but not including: gametes; blood and blood components.
<b>Complaint</b>	An expression of dissatisfaction made to the organisation, related to its product or testing, or service, or the complaints-handling process itself, where a response or resolution is explicitly or implicitly expected
<b>Critical</b>	Potentially having an effect on the quality and/or safety of or having contact with the cells and tissues.
<b>Customer</b>	Means the person / Establishment named as Customer in the Award Letter
<b>Designated Individual (DI)</b>	Designated Individual, the individual designated on the HTA licence as the person under whose supervision the licensed activity is authorised to be carried on.
<b>Facility / Facilities</b>	These include clinical facilities, laboratory facilities, storage facilities, facilities for donation, facilities for reception and procurement, facilities for distribution, import and/or export, and facilities for staff.
<b>Licence Holder</b>	Means a person or corporate body who holds a licence under Schedule 1 of the Regulations.
<b>Party</b>	means the Supplier or the Customer (as appropriate) and “Parties” shall mean both of them
<b>Quality Manager</b>	A person who is designated to coordinate and oversee the activities under the quality management system. He/she may monitor and advise on the performance of the quality management system and produces reports on performance, measuring against set indicators. The quality manager may also advise on changes and their implementation and provides training, tools and techniques to enable others to achieve quality.
<b>Quality management</b>	The coordinated activities to direct and control an organisation with regard to quality.



## Medicines & Healthcare products Regulatory Agency

<b>Quality management system</b>	A set of processes that define the establishment's approach to the management of the organisation. It should ensure continuous and systematic improvement through use of a quality system and quality review 'tools' such as audit and risk assessment, so that the establishment provides products and services which meet required standards.
<b>Quality system</b>	The organisational structure, defined responsibilities, procedures, processes, and resources for implementing quality management and includes all activities which contribute to quality, directly or indirectly.
<b>Regulations</b>	Used throughout to refer to:  The Human Tissue (Quality and Safety for Human Application) Regulations 2007 (as amended),  The HTA 'Guide to Quality and Safety Assurance of Human Tissues and Cells for Patient Treatment'.
<b>Sample</b>	Any biological material and its derivatives shared by the Customer to the Supplier.
<b>SAE/SAR</b>	Serious Adverse Event and / or Serious Adverse Reaction.
<b>Serious Adverse Event (SAE)</b>	<p>As defined in the HTA Guide to Quality and Safety Assurance for Tissues and Cells for Patient Treatment (Version 3 2021):</p> <p><i>"Any untoward occurrence which may be associated with the procurement, testing, processing, storage or distribution of tissue or cells intended for human application and which, in relation to a donor of tissue or cells intended for human application or a recipient of tissue or cells:</i></p> <p><i>a. might lead to the transmission of a communicable disease, to death or life-threatening, disabling or incapacitating conditions;</i></p> <p><i>b. might result in, or prolong, hospitalisation or morbidity."</i></p>
<b>Serious Adverse Reaction (SAR)</b>	<p>As defined in the HTA Guide to Quality and Safety Assurance for Tissues and Cells for Patient Treatment (updated on 3 June 2021):</p> <p><i>"An unintended response, including a communicable disease, in a donor of tissue or cells intended for human application or a recipient of tissue or cells, which may be associated with the procurement or human application of tissue or cells and which is fatal, life-threatening, disabling, incapacitating or which results in, or prolongs, hospitalisation or morbidity."</i></p>



## Medicines & Healthcare products Regulatory Agency

<b>Service Level Agreement</b>	This term is frequently used in this guide for agreements between two licensed entities.
<b>Standard Operating Procedure</b>	Written instructions describing the steps in a specific process, including the materials and methods to be used and the expected end product.
<b>Sub-contract</b>	A person or business may enter a general contract with a contractor for the providing of construction or repairs or other labour, whereby the general contractor then subcontracts out the duties to subcontractors for part of the work. The general contractor's contract with the subcontractor is called a subcontract.
<b>Supplier</b>	The person /establishment named as the supplier and providing the service
<b>The Guide</b>	Refers to the HTA 'Guide to Quality and Safety Assurance of Human Tissues and Cells for Patient Treatment'.
<b>Tissue</b>	<p>As defined in the HTA Guide to Quality and Safety Assurance for Tissues and Cells for Patient Treatment (Version 3, 2021):</p> <p><i>“All constituent parts of the human body formed by cells, but does not include gametes; or embryos outside the human body; or organs or parts of organs if it is their function to be used for the same purpose as the entire organ in the human body.”</i></p>
<b>Third-Party</b>	A person or corporate body with whom a License Holder, or the Designated Individual on behalf of the License Holder, has a third-party agreement. A third-party is defined here as an entity which is not licensed for human application by the HTA.
<b>Third-Party Agreement</b>	<p>An agreement in writing between a License Holder, or the Designated Individual on behalf of the License Holder, and another person or corporate body who do not hold an HTA licence for human application. A third-party agreement is entered into for the purpose of securing adherence to the specified requirements of the Regulations, and under which the other person:</p> <p>a. carries on a licensed activity (other than storage or import from a third country), on behalf of the License Holder. For example, if they procure, process, test, distribute, or export tissues and/or cells on behalf of the License Holder; or</p>



## Medicines & Healthcare products Regulatory Agency

b. supplies to the License Holder any goods or services which may affect the quality or safety of tissue or cells.

### **Traceability**

The ability to locate and identify the tissue/cell during any step from procurement, through processing, testing and storage, to distribution to the recipient or disposal, which also implies the ability to identify the donor and the tissue establishment or the manufacturing facility receiving, processing or storing the tissue/cells, and the ability to identify the recipient(s) at the medical facility/facilities applying the tissue/cells to the recipient(s). Traceability also covers the ability to locate and identify all relevant data relating to products and materials coming into contact with those tissues/cells.

### **Validation (or “qualification” in case of equipment or environments)**

Establishing documented evidence that provides a high degree of assurance that a specific process, Standard Operating Procedure, piece of equipment or environment will consistently produce a product meeting its predetermined specifications and quality attributes; a process is validated to evaluate the performance of a system with regard to its effectiveness based on intended use.

### **Working Day**

means a day (other than a Saturday or Sunday) on which banks are open for business in the City of London.



# Medicines & Healthcare products Regulatory Agency

## 1. SPECIFICATIONS

- 1.1 Accredited Sterility testing Method as per British Pharmacopoeia / Ph. Eur 2.6.1 by direct inoculation using appropriate media and (i.e. FTM & TSB) and incubation temperatures.
- 1.2 Critical testing activities are performed within a clean environment at Grade A i.e. in a cleanroom or within an isolator.
- 1.3 Growth promotion testing is carried out for each batch of media used with a minimal range of strains with demonstrate support for Aerobic, Anaerobic and Fungi growth
- 1.4 All aspects of UKSCB sample handling and storage must be within a quality management system that meets HTA requirements.
- 1.5 All contract testing is carried out by suitably qualified and trained staff and appropriate training records must show that they are competent to carry out the specified tests.
- 1.6 All tests required for the cell lines/cell banks must be appropriately validated and approved suitable for use by the UKSCB. The evidence to support validation of test methods shall be provided on request.
- 1.7 The supplier must inform & receive approval from the UKSCB in advance if testing is subcontracted to the Third Party. Testing protocols will require to be formally approved by UKSCB before any testing activities can commence.
- 1.8 Cell line information provided on the sample labels must be recorded on the test results documentation to allow traceability of UKSCB samples. This shall include:
  - Cell line name and UKSCB Identifier
  - Type of cell bank (Pre-Master, Master, Working or Distribution) from which the sample is provided
  - Date samples sent
  - Purchase Order Number
- 1.9 Results will be appropriately reviewed, analysed and commented on by named, suitably qualified and trained individual and reviewed by Quality Assurance.
- 1.10 The Customer must be notified immediately (email and telephone) within 24 hours in the event of a positive sterility testing result. Species identification must be performed in the event of a positive result.





## Medicines & Healthcare products Regulatory Agency

- 1.11 All Out of Specification (OOS) results shall be investigated as per local SOP and formally reported to the UKSCB, with the corrective action that has been undertaken, as part of the final test report.
- 1.12 The Supplier must issue a signed and dated report within 5 weeks of sample receipt (depending on the number of samples to be tested).
- 1.13 The Supplier will provide copies of the SOPs required to meet this specification before commencement of the testing service.

### **2. RESPONSIBILITIES OF ALL PARTIES**

- 2.1 Communication on all matters relating to this Third-Party Agreement shall take place between Supplier Quality Manager or Customer designees. An authorised users list will specify these designated persons.
- 2.2 The Customer Designated Individual (DI) and the Supplier will be informed of any Serious Adverse Event and / or Serious Adverse Reaction (SAE/SAR) which have the potential to affect the safety status of the Customer's samples. Any SAE/SAR that affects quality and safety of the Tissues and cell dedicated for human application must be reported to the HTA within 24 hours of discovery. In a case of SAE/SARs or any non-compliance with the legal requirements, the HTA has the power to enter and inspect the third-party premises.
- 2.3 Any changes or amendments to the Agreement must be in writing and signed by both the Supplier and the Customer.

### **3. RESPONSIBILITIES OF THE SUPPLIER**

- 3.1 Abide by the terms of this agreement.
- 3.2 Follow agreed protocols.
- 3.3 Testing activities carried out by the Supplier must be licensed by a competent national authority, the supplier must ensure all relevant licenses and/or accreditations are held. The customer must be informed immediately in the event of License suspension or termination.



## Medicines & Healthcare products Regulatory Agency

- 3.4 The Supplier will inform the Customer of any results of any official inspections by any regulatory and/or licensing authority and/or Complaints that could potentially impact upon the Customer's samples. Notification will be within one month for results of inspections and within two working days for Complaints.
- 3.5 The supplier will refrain from any activity which will knowingly adversely affect the quality of the Services
- 3.6 In the event of an audit by regulatory authorities, the Supplier has a right to show details including the Customer's documentation to the Regulatory Authority relevant to the Customer's samples only.
- 3.7 Ensure a documented quality management system is in place in respect of all activities for which a license was granted.
- 3.8 Formally investigate any complaints made by the end user or UKSCB and notify UKSCB within 20 working days of the complaint being made.
- 3.9 Any SAE/SARs must be reported to the HTA by UKSCB, within 24 hours of occurrence. The supplier must report any incident that may constitute an SAE/SAR to the customer within 24 hours of discovery. This includes, but is not limited to, positive results, or issues that might affect the integrity of any previously reported results e.g. an audit finding that questions the suitability of method or equipment validation, uncertainty over sample identification for reported results.
- 3.10 The Supplier will not sub-contract work. Where this is unavoidable written agreement must be given by UKSCB and testing protocols will require to be formally approved by UKSCB before any testing activities can commence. The supplier is responsible for ensuring any sub-contracted work meets the same quality standards as in-house testing.
- 3.11 Ensure all third parties have attained all licenses and/or accreditations in order to fulfil tasks to the same standard as the Supplier. If requested, the supplier must be able to provide evidence of third-party training.
- 3.12 The supplier must not to provide samples/cells to any third party without written UKSCB permission.
- 3.13 Permit audit of their procedures on request but no more frequently than once a year. The audit findings to be provided back to provider for records and actions to be completed
- 3.14 Should the Supplier cease trading or are unable to continue providing the service the Customer will be contacted as soon as possible and within one calendar month.



## Medicines & Healthcare products Regulatory Agency

### **4. RESPONSIBILITIES OF THE CUSTOMER**

- 4.1 All samples sent to the Supplier should have minimum details on the following tests or a risk assessment:
- HIV 1 and 2
  - Syphilis
  - Hepatitis B
  - Hepatitis C
  - HTLV1
- 4.2 Ensure samples are suitably prepared to agreed protocols prior to dispatch.
- 4.3 Inform the service provider of any risks associated with the samples including any relevant biohazards.
- 4.4 Notify the supplier in advance at least 24 hours in advance of dispatch.
- 4.5 Complete any required submission paperwork or electronic logging system required by the supplier to register the samples.
- 4.6 Any SAE/SARs must be reported to the HTA by Customer, within 24 hours of occurrence. Any relevant SAE/SARs must also be reported to the Supplier within one business day.

### **5. COMPLAINTS**

- 5.1 The Supplier will provide all necessary information to the Customer without delay.
- 5.2 The Supplier will log all Complaints and together with the Customer initiate a thorough investigation as per written procedures.

### **6. DOCUMENTATION**

- 6.1 The Supplier is responsible for maintaining a full and complete set of operational documentation. Upon request the Supplier will forward documentation relevant to the Services to the Customer for their records.
- 6.2 Should the Supplier cease trading or are unable to continue performing the Services, the Customer will be contacted as soon as possible and within one calendar month regarding project documentation. All documentation relating to the Services will be securely and systematically filed and forwarded to the Customer.



## Medicines & Healthcare products Regulatory Agency

- 6.3 The Supplier will store documentation related to the Services for a minimum 10 years.
- 6.4 The Supplier must have system in place to ensure sign off and confirmation that the result applies to the correct sample.
- 6.5 Testing results must be appropriately documented, reviewed, and analysed by suitably qualified and trained individuals including a member of Quality Assurance.
- 6.6 All changes to documents and records must be documented, reviewed, approved, and dated by suitable personnel.

### **7. SAMPLE RECEIPT**

- 7.1 All incoming samples will be inspected on receipt by the Supplier within 24-48 hours. On receipt of samples and associated documentation all containers will be checked for external condition, delivery documentation, and quantity received.
- 7.2 Notify UKSCB immediately if sample(s) is lost, damaged or if there is any other issue that could impact testing results.
- 7.3 The Supplier will review all receipt documentation to ensure completeness and accuracy and confirm with Customer within five days of receipt.

### **8. QUALITY REQUIREMENTS FOR THE TESTING SERVICE**

- 8.1 The Customer must be informed immediately in the event of license suspension or termination.
- 8.2 Copy of up-to-date Certificate of Accreditation must be provided to the Customer upon request.
- 8.3 The Supplier must have an organisational structure and operational procedures appropriate for the activities for which the license has been granted. There must be an organizational chart which defines accountability and reporting relationships.
- 8.4 A documented quality management system must be in place in respect of all activities for which a license was granted.
- 8.5 Premises and laboratories must be located, designed, and maintained to suit the operations to be carried out. The layout and design must aim to minimise the risk of errors and permit effective cleaning and maintenance in order to avoid cross-contamination, build-up of dust or dirt.



## Medicines & Healthcare products Regulatory Agency

- 8.6 All aspects of Customer samples storage at the Supplier's laboratory must be within a quality management system that meets HTA Directions. Where special storage conditions are required (e.g., temperature, humidity) these should be provided, checked, and monitored.
- 8.7 The handling (receipt, storage, sampling, testing, disposal) of the Customer's samples must be done in accordance with written procedures or instruction and, where necessary, recorded.
- 8.8 Critical testing activities (such as sample preparation) must be performed under controlled environment conditions so that the risk of contamination is minimised. It is the Suppliers' responsibility to ensure that correct controls are in place to maintain laboratories under defined conditions.
- 8.9 All equipment that might influence testing results must be designed, validated, calibrated, and maintained to suit its intended purpose. A validated cleaning protocol must be in place as to ensure that risk of cross-contamination between the different samples is minimised.
- 8.10 All contract testing is carried out by suitably qualified and trained staff and appropriate training records must show that they are competent to carry out the specified tests.
- 8.11 Testing method must be appropriately validated by the Supplier using human pluripotent stem cell (hPSC) analyte(s) provided by the Customer in order to demonstrate that assay is fit for purpose. The evidence to support the test method Validation must be provided to the Customer.
- 8.12 All testing activities must be carried out in accordance with approved standard operating procedures, which must be reviewed and approved prior to commencement of the testing services.
- 8.13 Significant amendments to the testing procedure or process, including any changes in equipment or materials, which may affect testing results, should be appropriately validated by the Supplier. The Customer must be informed regarding any changes prior to the implementation.
- 8.14 Out-of-specification or significant atypical results must be investigated to determine potential root cause and to prevent re-occurrence. All out-of-specification results should be formally reported to the Customer with the corrective action that has been undertaken as part of the final test report.
- 8.15 The Customer must be notified immediately (email and telephone) within 24 hours in the event of the positive testing result.
- 8.16 The Supplier must allow audit of their procedures upon request but no more frequently than once a year. The Customer will provide the audit findings to the Supplier. The Supplier will be required to implement the corrective action plan to address any finding.



## Medicines & Healthcare products Regulatory Agency

### **9. DISPOSAL**

- 9.1 The Supplier is responsible for arranging appropriate disposal of samples. All samples should be treated as clinical waste.

### **10. DEVIATIONS**

- 10.1 All deviations (including but not limited to documented procedures, facility, utilities & equipment failures) must be documented by the Supplier and assessed by both the Supplier and the Customer. All major deviations potentially impacting sample quality, safety or efficacy must be notified to the Customer on the day of identification.
- 10.2 In the event that additional corrective / preventative actions are required, the planned course of action must be agreed between the Customer and the Supplier. In the event of time critical deviations, approval of necessary actions is delegated solely to the Supplier's Quality Manager or designee. The Customer must be notified of such occurrences as soon as reasonably practical for their approval.
- 10.3 The Supplier must make available relevant deviation investigations related to the Services to Customer.

### **11. CHANGE CONTROL**

- 11.1 The Supplier must provide written notification to the Customer of any significant changes to the specifications, procedures, facilities, utilities, or equipment used for the Services. The Customer must approve any changes that may impact the quality of the Services before implementation.

### **12. REVIEW**

- 12.1 Any changes or amendments will be subject to the issue of a new revision of this agreement. All revisions must be signed and dated by both the Supplier and the Customer prior to becoming effective.
- 12.2 The Customer shall monitor all service level agreements to ensure satisfactory performance. Monitoring may lead to a review of the agreement.
- 12.3 The Customer shall review all Service Level Agreements on biannual basis. The persons responsible for review are: UKSCB Quality Coordinator and Head of Cell Production.
- 12.4 This Agreement may be re-negotiated following a review.



### **13. GENERAL ADHERENCE TO HUMAN TISSUE ACT REQUIREMENTS**

- 13.1 The Supplier will meet the requirements of the licence held by the Customer for the carrying on of the Services.
- 13.2 The Supplier confirms that it is able to meet the requirements of the HTA licence in relation to the Services.
- 13.3 The Supplier and Customer both confirm they are independent entities which have entered into a contract for the carrying out of the Services described above.
- 13.4 The Supplier and Customer both confirm that it has a system to ensure sign off and confirmation that the result applies to the correct sample.
- 13.5 The Customer confirms that it has considered whether there are any specific criteria that the Third-Party is required to meet in relation to quality and safety.
- 13.6 The Customer confirms that it has evaluated and selected the Third-Party on the basis of their ability to meet the requirements of the HTA licence and the Guide to quality and safety assurance for human Cells or Tissues for patient treatment (for licensable activity only)



Medicines & Healthcare products  
Regulatory Agency

**Supplier Signature**

**Signatory Full Name**

[Redacted]

**Signatory Position**

[Redacted]

**On behalf of**

**Reading Scientific Services Ltd**

**Signature**

**Date**

[Redacted]

**Customer Signature**

**HTA Designated Individual**

On behalf of UK Stem Cell Bank, MHRA

Signature

Date





**UKSCB Use only:**

**Communication with the HTA**

Copy sent to HTA on (date)

**Sender** Full Name

**Sender** Position



## Medicines & Healthcare products Regulatory Agency

### II. Short form Terms (“Conditions”)

#### 1. Definitions used in the Contract

In this Contract, unless the context otherwise requires, the following words shall have the following meanings:

<b>“Affiliates”</b>	in relation to a body corporate, any other entity which directly or indirectly Controls (in either of the senses defined in sections 450 and 1124 of the Corporation Tax Act 2010 and <b>“Controlled”</b> shall be construed accordingly), is Controlled by, or is under direct or indirect common Control of that body corporate from time to time;
<b>“Audit”</b>	<p>the Buyer’s right to:</p> <ul style="list-style-type: none"><li>(a) verify the accuracy of the Charges and any other amounts payable by the Buyer under the Contract (including proposed or actual variations to them in accordance with the Contract);</li><li>(b) verify the costs of the Supplier (including the costs of all Subcontractors and any third party suppliers) in connection with the provision of the Deliverables;</li><li>(c) verify the Supplier’s and each Subcontractor’s compliance with the applicable Law;</li><li>(d) identify or investigate actual or suspected breach of clauses 4 to 35, impropriety or accounting mistakes or any breach or threatened breach of security and in these circumstances the Buyer shall have no obligation to inform the Supplier of the purpose or objective of its investigations;</li><li>(e) identify or investigate any circumstances which may impact upon the financial stability of the Supplier and/or any Subcontractors or their ability to provide the Deliverables;</li><li>(f) obtain such information as is necessary to fulfil the Buyer’s obligations to supply information for parliamentary, ministerial, judicial or administrative purposes including the supply of information to the Comptroller and Auditor General;</li><li>(g) review any books of account and the internal contract management accounts kept by the Supplier in connection with the Contract;</li><li>(h) carry out the Buyer’s internal and statutory audits and to prepare, examine and/or certify the Buyer’s annual and interim reports and accounts;</li><li>(i) enable the National Audit Office to carry out an examination pursuant to Section 6(1) of the National Audit Act 1983 of the economy, efficiency and</li></ul>



## Medicines & Healthcare products Regulatory Agency

	effectiveness with which the Buyer has used its resources;
<b>"Buyer"</b>	the person named as Buyer in the Order Form. Where the Buyer is a Crown Body the Supplier shall be treated as contracting with the Crown as a whole;
<b>"Buyer Cause"</b>	any breach of the obligations of the Buyer or any other default, act, omission, negligence or statement of the Buyer, of its employees, servants, agents in connection with or in relation to the subject-matter of the Contract and in respect of which the Buyer is liable to the Supplier;
<b>"Central Government Body"</b>	a body listed in one of the following sub-categories of the Central Government classification of the Public Sector Classification Guide, as published and amended from time to time by the Office for National Statistics:  (a) Government Department;  (b) Non-Departmental Public Body or Assembly Sponsored Public Body (advisory, executive, or tribunal);  (c) Non-Ministerial Department; or  (d) Executive Agency;
<b>"Charges"</b>	the charges for the Deliverables as specified in the Order Form;
<b>"Claim"</b>	any claim which it appears that the Buyer is, or may become, entitled to indemnification under this Contract;
<b>"Compliance Officer"</b>	the person(s) appointed by the Supplier who is responsible for ensuring that the Supplier complies with its legal obligations;
<b>"Conditions"</b>	means these short form terms and conditions of contract;
<b>"Confidential Information"</b>	all information, whether written or oral (however recorded), provided by the disclosing Party to the receiving Party and which (i) is known by the receiving Party to be confidential; (ii) is marked as or stated to be confidential; or (iii) ought reasonably to be considered by the receiving Party to be confidential;
<b>"Conflict of Interest"</b>	a conflict between the financial or personal duties of the Supplier or the Supplier Staff and the duties owed to the Buyer under the Contract, in the reasonable opinion of the Buyer;
<b>"Contract"</b>	the contract between (i) the Buyer and (ii) the Supplier which is created by the Supplier's counter signing the Order Form and includes the cover letter (if used), Order Form, these Conditions and the Annexes;



## Medicines & Healthcare products Regulatory Agency

"Controller"	has the meaning given to it in the UK GDPR or the EU GDPR as the context requires;
"Crown Body"	the government of the United Kingdom (including the Northern Ireland Assembly and Executive Committee, the Scottish Government and the National Assembly for Wales), including, but not limited to, government ministers and government departments and particular bodies, persons, commissions or agencies from time to time carrying out functions on its behalf;
"Data Loss Event"	any event that results, or may result, in unauthorised access to Personal Data held by the Processor under this Contract, and/or actual or potential loss and/or destruction of Personal Data in breach of this Contract, including any Personal Data Breach;
"Data Protection Impact Assessment"	an assessment by the Controller of the impact of the envisaged processing on the protection of Personal Data;
"Data Protection Legislation"	(a) the UK GDPR, (b) the DPA 2018; (c) all applicable Law about the processing of personal data and privacy and guidance issued by the Information Commissioner and other regulatory authority; and (d) (to the extent that it applies) the EU GDPR (and in the event of conflict, the UK GDPR shall apply);
"Data Protection Liability Cap"	has the meaning given to it in row 12 of the Order Form;
"Data Protection Officer"	has the meaning given to it in the UK GDPR or the EU GDPR as the context requires;
"Data Subject"	has the meaning given to it in the UK GDPR or the EU GDPR as the context requires;
"Data Subject Access Request"	a request made by, or on behalf of, a Data Subject in accordance with rights granted pursuant to the Data Protection Legislation to access their Personal Data;
"Date of Delivery"	that date by which the Deliverables must be Delivered to the Buyer, as specified in the Order Form;
"Deliver"	hand over of the Deliverables to the Buyer at the address and on the date specified in the Order Form, which shall include unloading and any other specific arrangements agreed in accordance with clause 4.2. " <b>Delivered</b> " and " <b>Delivery</b> " shall be construed accordingly;
"Deliverables"	means the Goods and/or Services to be supplied under the Contract as set out in the Order Form;
"DPA 2018"	the Data Protection Act 2018;



## Medicines & Healthcare products Regulatory Agency

"EU"	the European Union;
"EU GDPR"	Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation) as it has effect in EU law;
"Existing IPR"	any and all intellectual property rights that are owned by or licensed to either Party and which have been developed independently of the Contract (whether prior to the date of the Contract or otherwise);
"Expiry Date"	the date for expiry of the Contract as set out in the Order Form;
"FOIA"	the Freedom of Information Act 2000 together with any guidance and/or codes of practice issued by the Information Commissioner or relevant Government department in relation to such legislation;
"Force Majeure Event"	<p>any event, circumstance, matter or cause affecting the performance by either the Buyer or the Supplier of its obligations arising from:</p> <ul style="list-style-type: none"><li>(a) acts, events, omissions, happenings or non-happenings beyond the reasonable control of the Party seeking to claim relief in respect of a Force Majeure Event (the "<b>Affected Party</b>") which prevent or materially delay the Affected Party from performing its obligations under the Contract;</li><li>(b) riots, civil commotion, war or armed conflict, acts of terrorism, nuclear, biological or chemical warfare;</li><li>(c) acts of a Crown Body, local government or regulatory bodies;</li><li>(d) fire, flood or any disaster; or</li><li>(e) an industrial dispute affecting a third party for which a substitute third party is not reasonably available</li></ul> <p>but excluding:</p> <ul style="list-style-type: none"><li>(i) any industrial dispute relating to the Supplier, the Supplier Staff (including any subsets of them) or any other failure in the Supplier or the Subcontractor's supply chain;</li><li>(ii) any event, occurrence, circumstance, matter or cause which is attributable to the wilful act, neglect or failure to take reasonable precautions against it by the Party concerned; and</li></ul>



## Medicines & Healthcare products Regulatory Agency

	<p>(iii) any failure of delay caused by a lack of funds,</p> <p>and which is not attributable to any wilful act, neglect or failure to take reasonable preventative action by that Party;</p>
<b>"Goods"</b>	the goods to be supplied by the Supplier to the Buyer under the Contract;
<b>"Good Industry Practice"</b>	standards, practices, methods and procedures conforming to the Law and the exercise of the degree of skill and care, diligence, prudence and foresight which would reasonably and ordinarily be expected from a skilled and experienced person or body engaged within the relevant industry or business sector;
<b>"Government Data"</b>	(a) the data, text, drawings, diagrams, images or sounds (together with any database made up of any of these) which are embodied in any electronic, magnetic, optical or tangible media, including any of the Buyer's confidential information, and which: (i) are supplied to the Supplier by or on behalf of the Buyer; or (ii) the Supplier is required to generate, process, store or transmit pursuant to the Contract; or (b) any Personal Data for which the Buyer is the Controller;
<b>"Implementation Plan"</b>	means the Supplier's plan for how it will prepare for service provision, as more particularly described at paragraph 4 of the Specification, and approved by the Buyer pursuant to Special Term 2.
<b>"Independent Controller"</b>	a party which is Controller of the same Personal Data as the other Party and there is no element of joint control with regards to that Personal Data;
<b>"Information"</b>	has the meaning given under section 84 of the FOIA;
<b>"Information Commissioner"</b>	the UK's independent authority which deals with ensuring information relating to rights in the public interest and data privacy for individuals is met, whilst promoting openness by public bodies;
<b>"Insolvency Event"</b>	<p>in respect of a person:</p> <p>(a) if that person is insolvent;</p> <p>(b) where that person is a company, LLP or a partnership, if an order is made or a resolution is passed for the winding up of the person (other than voluntarily for the purpose of solvent amalgamation or reconstruction);</p>



## Medicines & Healthcare products Regulatory Agency

	<p>(c) if an administrator or administrative receiver is appointed in respect of the whole or any part of the person's assets or business;</p> <p>(d) if the person makes any composition with its creditors; or</p> <p>(e) takes or suffers any similar or analogous action to any of the actions detailed in this definition as a result of debt in any jurisdiction;</p>
"IP Completion Day"	has the meaning given to it in the European Union (Withdrawal Agreement) Act 2020;
"Joint Controller Agreement"	the agreement (if any) entered into between the Buyer and the Supplier substantially in the form set out in <b>Error! Reference source not found.</b> of Annex 1 – <i>Processing Personal Data</i> ;
"Joint Controllers"	Where two or more Controllers jointly determine the purposes and means of processing;
"Key Staff"	any persons specified as such in the Order Form or otherwise notified as such by the Buyer to the Supplier in writing, following agreement to the same by the Supplier;
"Law"	any law, subordinate legislation within the meaning of section 21(1) of the Interpretation Act 1978, bye-law, right within the meaning of the European Union (Withdrawal) Act 2018 as amended by European Union (Withdrawal Agreement) Act 2020, regulation, order, regulatory policy, mandatory guidance or code of practice, judgment of a relevant court of law, or directives or requirements of any regulatory body with which the Supplier is bound to comply;
"Month"	a calendar month and "Monthly" shall be interpreted accordingly;
"National Insurance"	contributions required by the Social Security Contributions and Benefits Act 1992 and made in accordance with the Social Security (Contributions) Regulations 2001 (SI 2001/1004);
"New IPR"	all and intellectual property rights in any materials created or developed by or on behalf of the Supplier pursuant to the Contract but shall not include the Supplier's Existing IPR;
"New IPR Items"	means a deliverable, document, product or other item within which New IPR subsists;
"Open Licence"	means any material that is published for use, with rights to access and modify, by any person for free, under a generally recognised open licence including Open Government Licence as set out at <a href="http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/">http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/</a> and the Open Standards Principles



## Medicines & Healthcare products Regulatory Agency

	documented at <a href="https://www.gov.uk/government/publications/open-standards-principles/open-standards-principles">https://www.gov.uk/government/publications/open-standards-principles/open-standards-principles</a> ;
<b>"Order Form"</b>	the order form signed by the Buyer and the Supplier printed above these Conditions;
<b>"Party"</b>	the Supplier or the Buyer (as appropriate) and <b>"Parties"</b> shall mean both of them;
<b>"Personal Data"</b>	has the meaning given to it in the UK GDPR or the EU GDPR as the context requires;
<b>"Personal Data Breach"</b>	has the meaning given to it in the UK GDPR or the EU GDPR as the context requires and includes any breach of Data Protection Legislation relevant to Personal Data processed pursuant to the Contract;
<b>"Prescribed Person"</b>	a legal adviser, an MP or an appropriate body which a whistle-blower may make a disclosure to as detailed in 'Whistleblowing: list of prescribed people and bodies', 24 November 2016, available online at: <a href="https://www.gov.uk/government/publications/blowing-the-whistle-list-of-prescribed-people-and-bodies--2/whistleblowing-list-of-prescribed-people-and-bodies">https://www.gov.uk/government/publications/blowing-the-whistle-list-of-prescribed-people-and-bodies--2/whistleblowing-list-of-prescribed-people-and-bodies</a> as updated from time to time;
<b>"Processor"</b>	has the meaning given to it in the UK GDPR or the EU GDPR as the context requires;
<b>"Processor Personnel"</b>	all directors, officers, employees, agents, consultants and suppliers of the Processor and/or of any Subprocessor engaged in the performance of its obligations under the Contract;
<b>"Protective Measures"</b>	technical and organisational measures which must take account of: <ul style="list-style-type: none"><li>(a) the nature of the data to be protected;</li><li>(b) harm that might result from Data Loss Event;</li><li>(c) state of technological development;</li><li>(d) the cost of implementing any measures;</li></ul> including pseudonymising and encrypting Personal Data, ensuring confidentiality, integrity, availability and resilience of systems and services, ensuring that availability of and access to Personal Data can be restored in a timely manner after an incident, and regularly assessing and evaluating the effectiveness of the such measures adopted by it;
<b>"Purchase Order Number" or "PO Number"</b>	the Buyer's unique number relating to the order for Deliverables to be supplied by the Supplier to the Buyer in accordance with the Contract;





## Medicines & Healthcare products Regulatory Agency

<b>"Rectification Plan"</b>	<p>the Supplier's plan (or revised plan) to rectify its material default which shall include:</p> <ul style="list-style-type: none"><li>(a) full details of the material default that has occurred, including a root cause analysis;</li><li>(b) the actual or anticipated effect of the material default; and</li><li>(c) the steps which the Supplier proposes to take to rectify the material default (if applicable) and to prevent such material default from recurring, including timescales for such steps and for the rectification of the material default (where applicable);</li></ul>
<b>"Regulations"</b>	<p>the Public Contracts Regulations 2015 and/or the Public Contracts (Scotland) Regulations 2015 (as the context requires) as amended from time to time;</p>
<b>"Request For Information"</b>	<p>has the meaning set out in the FOIA or the Environmental Information Regulations 2004 as relevant (where the meaning set out for the term "request" shall apply);</p>
<b>"Services"</b>	<p>the services to be supplied by the Supplier to the Buyer under the Contract;</p>
<b>"Specification"</b>	<p>the specification for the Deliverables to be supplied by the Supplier to the Buyer (including as to quantity, description and quality) as specified in the Order Form;</p>
<b>"Staff Vetting Procedures"</b>	<p>vetting procedures that accord with Good Industry Practice or, where applicable, the Buyer's procedures or policies for the vetting of personnel as specified in the Order Form or provided to the Supplier in writing following agreement to the same by the Supplier from time to time;</p>
<b>"Start Date"</b>	<p>the start date of the Contract set out in the Order Form;</p>
<b>"Sub-Contract"</b>	<p>any contract or agreement (or proposed contract or agreement), other than the Contract, pursuant to which a third party:</p> <ul style="list-style-type: none"><li>(a) provides the Deliverables (or any part of them);</li><li>(b) provides facilities or services necessary for the provision of the Deliverables (or any part of them); and/or</li><li>(c) is responsible for the management, direction or control of the provision of the Deliverables (or any part of them);</li></ul>
<b>"Subcontractor"</b>	<p>any person other than the Supplier, who is a party to a Sub-</p>



## Medicines & Healthcare products Regulatory Agency

	Contract and the servants or agents of that person;
"Subprocessor"	any third party appointed to process Personal Data on behalf of the Processor related to the Contract;
"Supplier"	the person named as Supplier in the Order Form;
"Supplier Staff"	all directors, officers, employees, agents, consultants and contractors of the Supplier and/or of any Subcontractor of the Supplier engaged in the performance of the Supplier's obligations under the Contract;
"Transparency Information"	<p>In relation to Contracts with a value above the relevant threshold set out in Part 2 of the Regulations only, the content of the Contract, including any changes to this Contract agreed from time to time, as well as any information relating to the Deliverables and performance pursuant to the Contract required to be published by the Buyer to comply with its transparency obligations, including those set out in Public Procurement Policy Note 09/21 (update to legal and policy requirements to publish procurement information on Contracts Finder) (<a href="https://www.gov.uk/government/publications/ppn-0921-requirements-to-publish-on-contracts-finder">https://www.gov.uk/government/publications/ppn-0921-requirements-to-publish-on-contracts-finder</a>) and Public Procurement Policy Note 01/17 (update to transparency principles) where applicable (<a href="https://www.gov.uk/government/publications/procurement-policy-note-0117-update-to-transparency-principles">https://www.gov.uk/government/publications/procurement-policy-note-0117-update-to-transparency-principles</a>) except for:</p> <ul style="list-style-type: none"><li>(a) any information which is exempt from disclosure in accordance with the provisions of the FOIA, which shall be determined by the Buyer; and</li><li>(b) Confidential Information;</li></ul>
"Term"	the period from the Start Date to the Expiry Date as such period may be extended in accordance with clause 11.2 or terminated in accordance with the Contract;
"Third Party IPR"	intellectual property rights owned by a third party which is or will be used by the Supplier for the purpose of providing the Deliverables;
"UK GDPR"	has the meaning as set out in section 3(10) of the DPA 2018, supplemented by section 205(4);
"VAT"	value added tax in accordance with the provisions of the Value Added Tax Act 1994;
"Worker"	any one of the Supplier Staff which the Buyer, in its reasonable opinion, considers is an individual to which Procurement Policy Note 08/15 ( <a href="https://www.gov.uk/government/publications/procurement-policy-note-0815-tax-arrangements-of-public-appointees">Tax Arrangements of Public Appointees</a> ) ( <a href="https://www.gov.uk/government/publications/procurement-policy-note-0815-tax-arrangements-of-public-appointees">https://www.gov.uk/government/publications/procurement-policy-note-0815-tax-arrangements-of-public-appointees</a> )



## Medicines & Healthcare products Regulatory Agency

	<a href="#">policynote-0815-tax-arrangements-of-appointees</a> ) applies in respect of the Deliverables; and
"Working Day"	a day (other than a Saturday or Sunday) on which banks are open for business in the City of London.

### 2. Understanding the Contract

In the Contract, unless the context otherwise requires:

- 2.1 references to numbered clauses are references to the relevant clause in these Conditions;
- 2.2 any obligation on any Party not to do or omit to do anything shall include an obligation not to allow that thing to be done or omitted to be done;
- 2.3 the headings in this Contract are for information only and do not affect the interpretation of the Contract;
- 2.4 references to "writing" include printing, display on a screen and electronic transmission and other modes of representing or reproducing words in a visible form;
- 2.5 the singular includes the plural and vice versa;
- 2.6 a reference to any Law includes a reference to that Law as amended, extended, consolidated or re-enacted from time to time and to any legislation or byelaw made under that Law;
- 2.7 the word "including", "for example" and similar words shall be understood as if they were immediately followed by the words "without limitation";
- 2.8 any reference which, immediately before IP Completion Day (or such later date when relevant EU law ceases to have effect pursuant to section 1A of the European Union (Withdrawal) Act 2018), is a reference to (as it has effect from time to time):
  - (a) any EU regulation, EU decision, EU tertiary legislation or provision of the EEA agreement ("**EU References**") which is to form part of domestic law by application of section 3 of the European Union (Withdrawal) Act 2018 and which shall be read on and after IP Completion Day as a reference to the EU References as they form part of domestic law by virtue of section 3 of the European Union (Withdrawal) Act 2018 as modified by domestic law from time to time; and
  - (b) any EU institution or EU authority or other such EU body shall be read on and after IP Completion Day as a reference to the UK institution, authority or body to which its functions were transferred.

### 3. How the Contract works

- 3.1 The Order Form is an offer by the Buyer to purchase the Deliverables subject to and in accordance with the terms and conditions of the Contract.
- 3.2 The Supplier is deemed to accept the offer in the Order Form when the Buyer receives a copy of the Order Form signed by the Supplier.
- 3.3 The Supplier warrants and represents that its tender (if any) and all statements made and documents submitted as part of the procurement of Deliverables are and remain true and accurate.



## Medicines & Healthcare products Regulatory Agency

### 4. What needs to be delivered

#### 4.1 All Deliverables

- (a) The Supplier must provide Deliverables: (i) in accordance with the Specification, the tender in Annex 4 – Supplier Tender (where applicable) and the Contract; (ii) using reasonable skill and care; (iii) using Good Industry Practice; (iv) using its own policies, processes and internal quality control measures as long as they don't conflict with the Contract; (v) on the dates agreed; and (vi) that comply with all Law.
- (b) The Supplier must provide Deliverables with a warranty (depending on type of Service) of at least 90 days (or longer where the Supplier offers a longer warranty period to its Buyers) from Delivery against all obvious defects.

#### 4.2 ~~Goods clauses~~

- ~~(a) All Goods delivered must be new, or as new if recycled, unused and of recent origin.~~
- ~~(b) All manufacturer warranties covering the Goods must be assignable to the Buyer on request and for free.~~
- ~~(c) The Supplier transfers ownership of the Goods on completion of Delivery (including off-loading and stacking) or payment for those Goods, whichever is earlier.~~
- ~~(d) Risk in the Goods transfers to the Buyer on Delivery, but remains with the Supplier if the Buyer notices damage following Delivery and lets the Supplier know within 3 Working Days of Delivery.~~
- ~~(e) The Supplier warrants that it has full and unrestricted ownership of the Goods at the time of transfer of ownership.~~
- ~~(f) The Supplier must Deliver the Goods on the date and to the location specified in the Order Form, during the Buyer's working hours (unless otherwise specified in the Order Form).~~
- ~~(g) The Supplier must provide sufficient packaging for the Goods to reach the point of Delivery safely and undamaged.~~
- ~~(h) All deliveries must have a delivery note attached that specifies the order number, type and quantity of Goods.~~
- ~~(i) The Supplier must provide all tools, information and instructions the Buyer needs to make use of the Goods.~~
- ~~(j) The Supplier will notify the Buyer of any request that Goods are returned to it or the manufacturer after the discovery of safety issues or defects that might endanger health or hinder performance and shall indemnify the Buyer against the costs arising as a result of any such request.~~
- ~~(k) The Buyer can cancel any order or part order of Goods which has not been Delivered. If the Buyer gives less than 14 days' notice then it will pay the Supplier's reasonable and proven costs already incurred on the cancelled order as long as the Supplier takes all reasonable endeavours to minimise these costs.~~



## Medicines & Healthcare products Regulatory Agency

- (l) ~~The Supplier must at its own cost repair, replace, refund or substitute (at the Buyer's option and request) any Goods that the Buyer rejects because they don't conform with clause 4.2. If the Supplier doesn't do this it will pay the Buyer's costs including repair or re-supply by a third party.~~
- (m) ~~The Buyer will not be liable for any actions, claims, costs and expenses incurred by the Supplier or any third party during Delivery of the Goods unless and to the extent that it is caused by negligence or other wrongful act of the Buyer or its servant or agent. If the Buyer suffers or incurs any damage or injury (whether fatal or otherwise) occurring in the course of Delivery or installation then the Supplier shall indemnify the Buyer from any losses, charges, costs or expenses which arise as a result of or in connection with such damage or injury where it is attributable to any act or omission of the Supplier or any of its Subcontractors or Supplier Staff.~~

### 4.3 Services clauses

- (a) Late Delivery of the Services will be a default of the Contract.
- (b) The Supplier must co-operate with the Buyer and third party suppliers on all aspects connected with the delivery of the Services and ensure that Supplier Staff comply with any reasonable instructions including the security requirements (where any such requirements have been provided).
- (c) The Buyer must provide the Supplier with reasonable access to its premises at reasonable times for the purpose of supplying the Services
- (d) The Supplier must at its own risk and expense provide all equipment required to deliver the Services. Any equipment provided by the Buyer to the Supplier for supplying the Services remains the property of the Buyer and is to be returned to the Buyer on expiry or termination of the Contract.
- (e) The Supplier must allocate sufficient resources and appropriate expertise to the Contract.
- (f) The Supplier must take all reasonable care to ensure performance does not disrupt the Buyer's operations, employees or other contractors.
- (g) On completion of the Services, the Supplier is responsible for leaving the Buyer's premises in a clean, safe and tidy condition and making good any damage that it has caused to the Buyer's premises or property, other than fair wear and tear.
- (h) The Supplier must ensure all Services, and anything used to deliver the Services, are of good quality and free from defects.
- (i) The Buyer is entitled to withhold payment for partially or undelivered Services, but doing so does not stop it from using its other rights under the Contract.

### 5. Pricing and payments

5.1 In exchange for the Deliverables, the Supplier must invoice the Buyer for the charges in the Order Form.

5.2 All Charges:

- (a) exclude VAT, which is payable on provision of a valid VAT invoice; and
- (b) include all costs and expenses connected with the supply of Deliverables.



## Medicines & Healthcare products Regulatory Agency

- 5.3 The Buyer must pay the Supplier the charges within 30 days of receipt by the Buyer of a valid, undisputed invoice, in cleared funds to the Supplier's account stated in the invoice or in the Order Form.
- 5.4 A Supplier invoice is only valid if it:
- (a) includes all appropriate references including the Purchase Order Number and other details reasonably requested by the Buyer; and
  - (b) includes a detailed breakdown of Deliverables which have been delivered.
- 5.5 If there is a dispute between the Parties as to the amount invoiced, the Buyer shall pay the undisputed amount. The Supplier shall not suspend the provision of the Deliverables unless the Supplier is entitled to terminate the Contract for a failure to pay undisputed sums in accordance with clause 11.6. Any disputed amounts shall be resolved through the dispute resolution procedure detailed in clause 37.
- 5.6 The Buyer may retain or set-off payment of any amount owed to it by the Supplier under this Contract or any other agreement between the Supplier and the Buyer if notice and reasons are provided.
- 5.7 The Supplier must ensure that all Subcontractors are paid, in full, within 30 days of receipt of a valid, undisputed invoice. If this doesn't happen, the Buyer can publish the details of the late payment or non-payment.
- 6. The Buyer's obligations to the Supplier**
- 6.1 If Supplier fails to comply with the Contract as a result of a Buyer Cause:
- (a) the Buyer cannot terminate the Contract under clause 11;
  - (b) the Supplier is entitled to reasonable and proven additional expenses and to relief from liability under this Contract;
  - (c) the Supplier is entitled to additional time needed to deliver the Deliverables; and
  - (d) the Supplier cannot suspend the ongoing supply of Deliverables.
- 6.2 Clause 6.1 only applies if the Supplier:
- (a) gives notice to the Buyer within 10 Working Days of becoming aware;
  - (b) demonstrates that the failure only happened because of the Buyer Cause; and
  - (c) mitigated the impact of the Buyer Cause.
- 7. Record keeping and reporting**
- 7.1 The Supplier must ensure that suitably qualified representatives attend progress meetings with the Buyer and provide progress reports when specified in the Order Form.
- 7.2 The Supplier must keep and maintain full and accurate records and accounts on everything to do with the Contract for 7 years after the date of expiry or termination of the Contract and in accordance with the UK GDPR or the EU GDPR as the context requires.
- 7.3 The Supplier must allow any auditor appointed by the Buyer access to its premises to verify all contract accounts and records of everything to do with the Contract and provide copies for the Audit.



## Medicines & Healthcare products Regulatory Agency

- 7.4 During an Audit, the Supplier must provide information to the auditor and reasonable co-operation at their request.
- 7.5 The Parties will bear their own costs when an Audit is undertaken unless the Audit identifies a material default by the Supplier, in which case the Supplier will repay the Buyer's reasonable costs in connection with the Audit.
- 7.6 If the Supplier is not providing any of the Deliverables, or is unable to provide them, it must immediately:
- (a) tell the Buyer and give reasons;
  - (b) propose corrective action; and
  - (c) provide a deadline for completing the corrective action.
- 7.7 If the Buyer, acting reasonably, is concerned as to the financial stability of the Supplier such that it may impact on the continued performance of the Contract then the Buyer may:
- (a) require that the Supplier provide to the Buyer (for its approval) a plan setting out how the Supplier will ensure continued performance of the Contract and the Supplier will make changes to such plan as reasonably required by the Buyer and once it is agreed then the Supplier shall act in accordance with such plan and report to the Buyer on demand; and
  - (b) if the Supplier fails to provide a plan or fails to agree any changes which are requested by the Buyer or fails to implement or provide updates on progress with the plan, terminate the Contract immediately for material breach (or on such date as the Buyer notifies).
- 7.8 If there is a material default, the Supplier must notify the Buyer within 3 Working Days of the Supplier becoming aware of the material default. The Buyer may request that the Supplier provide a Rectification Plan within 10 Working Days of the Buyer's request alongside any additional documentation that the Buyer requires. Once such Rectification Plan is agreed between the Parties (without the Buyer limiting its rights) the Supplier must immediately start work on the actions in the Rectification Plan at its own cost.
- 8. Supplier Staff**
- 8.1 The Supplier Staff involved in the performance of the Contract must:
- (a) be appropriately trained and qualified;
  - (b) be vetted in accordance with the Staff Vetting Procedures; and
  - (c) comply with all conduct requirements when on the Buyer's premises.
- 8.2 Where the Buyer decides one of the Supplier's Staff isn't suitable to work on the Contract, the Supplier must replace them with a suitably qualified alternative.
- 8.3 If requested, the Supplier must replace any person whose acts or omissions have caused the Supplier to breach clause 29.1 to 29.3 .
- 8.4 The Supplier must provide a list of Supplier Staff needing to access the Buyer's premises and say why access is required.





## Medicines & Healthcare products Regulatory Agency

- 8.5 The Supplier indemnifies the Buyer against all claims brought by any person employed or engaged by the Supplier caused by an act or omission of the Supplier or any Supplier Staff.
- 8.6 The Supplier shall use those persons nominated (if any) as Key Staff in the Order Form or otherwise notified as such by the Buyer to the Supplier in writing, following agreement to the same by the Supplier to provide the Deliverables and shall not remove or replace any of them unless:
- (a) requested to do so by the Buyer or the Buyer approves such removal or replacement (not to be unreasonably withheld or delayed);
  - (b) the person concerned resigns, retires or dies or is on parental or long-term sick leave; or
  - (c) the person's employment or contractual arrangement with the Supplier or any Subcontractor is terminated for material breach of contract by the employee.
- 8.7 The Supplier shall ensure that no person who discloses that he/she has a conviction that is relevant to the nature of the Contract, relevant to the work of the Buyer, or is of a type otherwise advised by the Buyer (each such conviction a "**Relevant Conviction**"), or is found by the Supplier to have a Relevant Conviction (whether as a result of a police check, a disclosure and barring service check or otherwise) is employed or engaged in the provision of any part of the Deliverables.
- 9. Rights and protection**
- 9.1 The Supplier warrants and represents that:
- (a) it has full capacity and authority to enter into and to perform the Contract;
  - (b) the Contract is executed by its authorised representative;
  - (c) it is a legally valid and existing organisation incorporated in the place it was formed;
  - (d) there are no known legal or regulatory actions or investigations before any court, administrative body or arbitration tribunal pending or threatened against it or its affiliates that might affect its ability to perform the Contract;
  - (e) all necessary rights, authorisations, licences and consents (including in relation to IPRs) are in place to enable the Supplier to perform its obligations under the Contract and the Buyer to receive the Deliverables;
  - (f) it doesn't have any contractual obligations which are likely to have a material adverse effect on its ability to perform the Contract; and
  - (g) it is not impacted by an Insolvency Event.
- 9.2 The warranties and representations in clause 3.3 and clause 9.1 are repeated each time the Supplier provides Deliverables under the Contract.
- 9.3 The Supplier indemnifies the Buyer against each of the following:
- (a) wilful misconduct of the Supplier, any of its Subcontractor and/or Supplier Staff that impacts the Contract; and
  - (b) non-payment by the Supplier of any tax or National Insurance.





## Medicines & Healthcare products Regulatory Agency

- 9.4 If the Supplier becomes aware of a representation or warranty made in relation to the Contract that becomes untrue or misleading, it must immediately notify the Buyer.
- 9.5 All third party warranties and indemnities covering the Deliverables must be assigned for the Buyer's benefit by the Supplier.
- 10. Intellectual Property Rights (IPRs)**
- 10.1 Each Party keeps ownership of its own Existing IPRs. The Supplier gives the Buyer a non-exclusive, perpetual, royalty-free, irrevocable, transferable worldwide licence to use, change and sub-license the Supplier's Existing IPR to enable the Buyer and its sub-licensees to both:
- (a) receive and use the Deliverables; and
  - (b) use the New IPR.
- 10.2 Any New IPR created under the Contract is owned by the Buyer. The Buyer gives the Supplier a licence to use any Existing IPRs and the New IPR which the Supplier reasonably requires for the purpose of fulfilling its obligations during the Term or using or exploiting the New IPR developed under the Contract.
- 10.3 Where a Party acquires ownership of intellectual property rights incorrectly under this Contract it must do everything reasonably necessary to complete a transfer assigning them in writing to the other Party on request and at its own cost.
- 10.4 Neither Party has the right to use the other Party's intellectual property rights, including any use of the other Party's names, logos or trademarks, except as provided in clause 10 or otherwise agreed in writing.
- 10.5 If any claim is made against the Buyer for actual or alleged infringement of a third party's intellectual property arising out of, or in connection with, the supply or use of the Deliverables (an "**IPR Claim**"), then the Supplier indemnifies the Buyer against all losses, damages, costs or expenses (including professional fees and fines) incurred as a result of the IPR Claim.
- 10.6 If an IPR Claim is made or anticipated the Supplier must at its own expense and the Buyer's sole option, either:
- (a) obtain for the Buyer the rights in clauses 10.1 and 10.2 without infringing any third party intellectual property rights; and
  - (b) replace or modify the relevant item with substitutes that don't infringe intellectual property rights without adversely affecting the functionality or performance of the Deliverables.
- 10.7 The Supplier shall not use in the Delivery of the Deliverables any Third Party IPR unless it has notified the Buyer that the owner or an authorised licensor of the relevant Third Party IPR will grant a direct licence to the Buyer for the Third Party IPR and that licence has been granted. The Buyer, in its absolute discretion, shall have 10 Working Days following the Supplier's notification to reject the grant of the licence. If the Supplier cannot obtain for the Buyer a licence in respect of any Third Party IPR, for whatever reason, the Supplier shall:
- (a) notify the Buyer in writing; and



## Medicines & Healthcare products Regulatory Agency

- (b) use the relevant Third Party IPR only if the Buyer has provided authorisation in writing, with reference to the acts authorised and the specific intellectual property rights involved.

10.8 In spite of any other provisions of the Contract and for the avoidance of doubt, award of this Contract by the Buyer and the ordering of any Deliverable under it does not constitute an authorisation by the Crown under Sections 55 and 56 of the Patents Act 1977, Section 12 of the Registered Designs Act 1949 or Sections 240 – 243 of the Copyright, Designs and Patents Act 1988.

### 11. Ending the contract

11.1 The Contract takes effect on the Start Date and ends on the earlier of the Expiry Date or termination of the Contract, or earlier if required by Law.

11.2 The Buyer can extend the Contract where set out in the Order Form in accordance with the terms in the Order Form.

#### 11.3 Ending the Contract without a reason

The Buyer has the right to terminate the Contract at any time without reason or liability by giving the Supplier not less than 90 days' written notice, and if it's terminated clause 11.5(a)(ii) to 11.5(a)(viii) applies.

#### 11.4 When the Buyer can end the Contract

- (a) If any of the following events happen, the Buyer has the right to immediately terminate its Contract by issuing a termination notice in writing to the Supplier:

- (i) there's a Supplier Insolvency Event;
- (ii) if the Supplier repeatedly breaches the Contract in a way to reasonably justify the opinion that its conduct is inconsistent with it having the intention or ability to give effect to the terms and conditions of the Contract;
- (iii) the Supplier is in material breach of any obligation which is capable of remedy, and that breach is not remedied within 30 days of the Supplier receiving notice specifying the breach and requiring it to be remedied;
- (iv) there's a change of control (within the meaning of section 450 of the Corporation Tax Act 2010) of the Supplier which isn't pre-approved by the Buyer in writing;
- (v) the Buyer discovers that the Supplier was in one of the situations in 57 (1) or 57(2) of the Regulations at the time the Contract was awarded;
- (vi) the Supplier or its affiliates embarrass or bring the Buyer into disrepute or diminish the public trust in them; or
- (vii) the Supplier fails to comply with its legal obligations in the fields of environmental, social, equality or employment Law when providing the Deliverables.

- (b) The Buyer also has the right to terminate the Contract in accordance with the Special Terms, clauses 7.7(b), 21.3, 29.4(b), 34.3 and Paragraph **Error! Reference source not found.** of **Error! Reference source not found.** of Annex 1 – *Processing Personal Data* (if used).



## Medicines & Healthcare products Regulatory Agency

- (c) If any of the events in 73(1) (a) or (b) of the Regulations happen, the Buyer has the right to immediately terminate the Contract and clause 11.5(a)(ii) to 11.5(a)(viii) applies.

### 11.5 What happens if the Contract ends (Buyer termination)

- (a) Where the Buyer terminates the Contract under clause 11.4(a), 7.7(b), 29.4(b), or Paragraph **Error! Reference source not found.** of **Error! Reference source not found.** of Annex 1 – *Processing Personal Data* (if used), all of the following apply:
  - (i) the Supplier is responsible for the Buyer's reasonable costs of procuring replacement Deliverables for the rest of the term of the Contract;
  - (ii) the Buyer's payment obligations under the terminated Contract stop immediately;
  - (iii) accumulated rights of the Parties are not affected;
  - (iv) the Supplier must promptly delete or return the Government Data except where required to retain copies by Law;
  - (v) the Supplier must promptly return any of the Buyer's property provided under the Contract;
  - (vi) the Supplier must, at no cost to the Buyer, give all reasonable assistance to the Buyer and any incoming supplier and co-operate fully in the handover and re-procurement;
  - (vii) the Supplier must repay to the Buyer all the Charges that it has been paid in advance for Deliverables that it has not provided as at the date of termination or expiry; and
  - (viii) the following clauses survive the termination of the Contract: 4.2(j), 7, 8.5, 10, 12, 14, 15, 16, 19, 20, 37 and 38 and any clauses which are expressly or by implication intended to continue.

### 11.6 When the Supplier can end the Contract and what happens when the contract ends (Buyer and Supplier termination)

- (a) The Supplier can issue a reminder notice if the Buyer does not pay an undisputed invoice on time. The Supplier can terminate the Contract if the Buyer fails to pay an undisputed invoiced sum due and worth over 10% of the total Contract value or £1,000, whichever is the lower, within 30 days of the date of the reminder notice.
- (b) Where the Buyer terminates the Contract in accordance with clause 11.3 or the Supplier terminates the Contract under clause 11.6(a) or 24.4:
  - (i) the Buyer must promptly pay all outstanding charges incurred by the Supplier;
  - (ii) the Buyer must pay the Supplier reasonable committed and unavoidable losses as long as the Supplier provides a fully itemised and costed schedule with evidence - the maximum value of this payment is limited to the total sum payable to the Supplier if the Contract had not been terminated; and



## Medicines & Healthcare products Regulatory Agency

(iii) clauses 11.5(a)(ii) to 11.5(a)(viii) apply.

- (c) The Supplier also has the right to terminate the Contract in accordance with Clauses 21.3 and 24.4.

### **11.7 Partially ending and suspending the Contract**

- (a) Where the Buyer has the right to terminate the Contract it can terminate or suspend (for any period), all or part of it. If the Buyer suspends the Contract it can provide the Deliverables itself or buy them from a third party.
- (b) The Buyer can only partially terminate or suspend the Contract if the remaining parts of it can still be used to effectively deliver the intended purpose.
- (c) The Parties must agree (in accordance with clause 26) any necessary variation required by clause 11.7, but the Supplier may not either:
- (i) reject the variation; or
  - (ii) increase the Charges, except where the right to partial termination is under clause 11.3.
- (d) The Buyer can still use other rights available, or subsequently available to it if it acts on its rights under clause 11.7.

### **12. How much you can be held responsible for**

- 12.1 Each Party's total aggregate liability under or in connection with the Contract (whether in tort, contract or otherwise) is no more than 125% of the Charges paid or payable to the Supplier.
- 12.2 No Party is liable to the other for:
- (a) any indirect losses; and/or
  - (b) loss of profits, turnover, savings, business opportunities or damage to goodwill (in each case whether direct or indirect).
- 12.3 In spite of clause 12.1, neither Party limits or excludes any of the following:
- (a) its liability for death or personal injury caused by its negligence, or that of its employees, agents or Subcontractors;
  - (b) its liability for bribery or fraud or fraudulent misrepresentation by it or its employees; or
  - (c) any liability that cannot be excluded or limited by Law.
- 12.4 In spite of clause 12.1, the Supplier does not limit or exclude its liability for any indemnity given under clauses 8.5, 9.3(b), 10.5, or 33.2(b).
- 12.5 Notwithstanding clause 12.1, but subject to clauses 12.1 and 12.3, the Supplier's total aggregate liability under clause 14.7(e) shall not exceed the Data Protection Liability Cap.
- 12.6 Each Party must use all reasonable endeavours to mitigate any loss or damage which it suffers under or in connection with the Contract, including any indemnities.
- 12.7 If more than one Supplier is party to the Contract, each Supplier Party is fully responsible for both their own liabilities and the liabilities of the other Suppliers.



## Medicines & Healthcare products Regulatory Agency

### 13. Obeying the Law

- 13.1 The Supplier must, in connection with provision of the Deliverables:
- (a) comply and procure that its Subcontractors comply with the Supplier Code of Conduct:  
([https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/779660/20190220-Supplier\\_Code\\_of\\_Conduct.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/779660/20190220-Supplier_Code_of_Conduct.pdf)) as such Code of Conduct may be updated from time to time, and such other sustainability requirements as set out in the Order Form;
  - (b) comply with the provisions of the Official Secrets Acts 1911 to 1989 and section 182 of the Finance Act 1989;
  - (c) support the Buyer in fulfilling its Public Sector Equality duty under section 149 of the Equality Act 2010;
  - (d) comply with the model contract terms contained in Example 1 of Annex C of the guidance to PPN 05/19 (Tackling Modern Slavery in Government Supply Chains) shall apply to the Contract, as such clauses may be amended or updated from time to time; and
  - (e) meet the applicable Government Buying Standards applicable to Deliverables which can be found online at:  
<https://www.gov.uk/government/collections/sustainable-procurement-the-government-buying-standards-gbs>.
- 13.2 The Supplier indemnifies the Buyer against any costs resulting from any default by the Supplier relating to any applicable Law to do with the Contract.
- 13.3 The Supplier must appoint a Compliance Officer who must be responsible for ensuring that the Supplier complies with Law, clause 13.1 and clauses 28 to 35.

### 14. Data Protection

- 14.1 The Supplier must not remove any ownership or security notices in or relating to the Government Data.
- 14.2 The Supplier must make accessible back-ups of all Government Data, stored in an agreed off-site location and send the Buyer copies every 6 Months.
- 14.3 The Supplier must ensure that any Supplier system holding any Government Data, including back-up data, is a secure system that complies with the security requirements specified in writing by the Buyer (where any such requirements have been provided).
- 14.4 If at any time the Supplier suspects or has reason to believe that the Government Data is corrupted, lost or sufficiently degraded, then the Supplier must immediately notify the Buyer and suggest remedial action.
- 14.5 If the Government Data is corrupted, lost or sufficiently degraded so as to be unusable the Buyer may either or both:
- (a) tell the Supplier to restore or get restored Government Data as soon as practical but no later than 5 Working Days from the date that the Buyer receives notice, or the Supplier finds out about the issue, whichever is earlier; and/or
  - (b) restore the Government Data itself or using a third party.



## Medicines & Healthcare products Regulatory Agency

- 14.6 The Supplier must pay each Party's reasonable costs of complying with clause 14.5 unless the Buyer is at fault.
- 14.7 The Supplier:
- (a) must provide the Buyer with all Government Data in an agreed open format within 10 Working Days of a written request;
  - (b) must have documented processes to guarantee prompt availability of Government Data if the Supplier stops trading;
  - (c) must securely destroy all storage media that has held Government Data at the end of life of that media using Good Industry Practice;
  - (d) securely erase all Government Data and any copies it holds when asked to do so by the Buyer unless required by Law to retain it; and
  - (e) indemnifies the Buyer against any and all losses incurred if the Supplier breaches clause 14 or any Data Protection Legislation.
- 14.8 The Parties acknowledge that for the purposes of the Data Protection Legislation, the nature of the activity carried out by each of them in relation to their respective obligations under the Contract dictates the status of each party under the DPA 2018. A Party may act as:
- (a) "Controller" in respect of the other Party who is "Processor";
  - (b) "Processor" in respect of the other Party who is "Controller";
  - (c) "Joint Controller" with the other Party;
  - (d) "Independent Controller" of the Personal Data where the other Party is also "Controller",
- in respect of certain Personal Data under the Contract and shall specify in Part A - *Authorised Processing Template* of Annex 1 – *Processing Personal Data* which scenario they think shall apply in each situation.
- 14.9 **Where one Party is Controller and the other Party its Processor**
- (a) Where a Party is a Processor, it must only process Personal Data if authorised to do so in Part A - *Authorised Processing Template* of Annex 1 – *Processing Personal Data* by the Controller. Any further written instructions relating to the processing of Personal Data are incorporated into Part A - *Authorised Processing Template* of Annex 1 – *Processing Personal Data*.
  - (b) The Processor must give all reasonable assistance to the Controller in the preparation of any Data Protection Impact Assessment before starting any processing, including:
    - (i) a systematic description of the expected processing and its purpose;
    - (ii) the necessity and proportionality of the processing operations;
    - (iii) the risks to the rights and freedoms of Data Subjects; and
    - (iv) the intended measures to address the risks, including safeguards, security measures and mechanisms to protect Personal Data.





## Medicines & Healthcare products Regulatory Agency

- (c) The Processor must notify the Controller immediately if it thinks the Controller's instructions breach the Data Protection Legislation.
- (d) The Processor must put in place appropriate Protective Measures to protect against a Data Loss Event which must be approved by the Controller.
- (e) If lawful to notify the Controller, the Processor must promptly notify the Controller if the Processor is otherwise required to process Personal Data by Law before processing it.
- (f) The Processor must use all reasonable endeavours to ensure the reliability and integrity of any Processor Personnel who have access to the Personal Data and ensure that they:
  - (i) are aware of and comply with the Processor's duties under this clause 14;
  - (ii) are subject to appropriate confidentiality undertakings with the Processor or any Subprocessor;
  - (iii) are informed of the confidential nature of the Personal Data and do not provide any of the Personal Data to any third party unless directed in writing to do so by the Controller or as otherwise allowed by the Contract; and
  - (iv) have undergone adequate training in the use, care, protection and handling of Personal Data.
- (g) Where the Personal Data is subject to UK GDPR, the Processor must not transfer Personal Data outside of the UK unless the prior written consent of the Controller has been obtained and the following conditions are fulfilled:
  - (i) the transfer is in accordance with Article 45 of the UK GDPR (or section 73 of DPA 2018); or
  - (ii) the Controller or the Processor has provided appropriate safeguards in relation to the transfer (whether in accordance with UK GDPR Article 46 or section 75 of the DPA 2018) as determined by the Controller which could include relevant parties entering into the International Data Transfer Agreement (the "**IDTA**"), or International Data Transfer Agreement Addendum to the European Commission's SCCs (the "**Addendum**"), as published by the Information Commissioner's Office from time to time as well as any additional measures determined by the Controller;
  - (iii) the Data Subject has enforceable rights and effective legal remedies when transferred;
  - (iv) the Processor meets its obligations under the Data Protection Legislation by providing an adequate level of protection to any Personal Data that is transferred; and
  - (v) the Processor complies with the Controller's reasonable prior instructions about the processing of the Personal Data.
- (h) Where the Personal Data is subject to EU GDPR, the Processor must not transfer Personal Data outside of the EU unless the prior written consent of the Controller has been obtained and the following conditions are fulfilled:



## Medicines & Healthcare products Regulatory Agency

- (i) the transfer is in accordance with Article 45 of the EU GDPR; or
  - (i) the Controller or Processor has provided appropriate safeguards in relation to the transfer in accordance with Article 46 of the EU GDPR as determined by the Controller which could include relevant parties entering into Standard Contractual Clauses in the European Commission's decision 2021/914/EU or such updated version of such Standard Contractual Clauses as are published by the European Commission from time to time as well as any additional measures determined by the Controller;
  - (ii) the Data Subject has enforceable rights and effective legal remedies;
  - (iii) the Processor complies with its obligations under the EU GDPR by providing an adequate level of protection to any Personal Data that is transferred (or, if it is not so bound, uses its best endeavours to assist the Controller in meeting its obligations); and
  - (iv) the Processor complies with any reasonable instructions notified to it in advance by the Controller with respect to the processing of the Personal Data.
- (j) The Processor must notify the Controller immediately if it:
  - (i) receives a Data Subject Access Request (or purported Data Subject Access Request);
  - (ii) receives a request to rectify, block or erase any Personal Data;
  - (iii) receives any other request, complaint or communication relating to either Party's obligations under the Data Protection Legislation;
  - (iv) receives any communication from the Information Commissioner or any other regulatory authority in connection with Personal Data processed under this Contract;
  - (v) receives a request from any third Party for disclosure of Personal Data where compliance with the request is required or claims to be required by Law; and
  - (vi) becomes aware of a Data Loss Event.
- (k) Any requirement to notify under clause (j) includes the provision of further information to the Controller in stages as details become available.
  - (i) The Processor must promptly provide the Controller with full assistance in relation to any Party's obligations under Data Protection Legislation and any complaint, communication or request made under clause (j). This includes giving the Controller:
    - (ii) full details and copies of the complaint, communication or request;
    - (iii) reasonably requested assistance so that it can comply with a Data Subject Access Request within the relevant timescales in the Data Protection Legislation;
    - (iv) any Personal Data it holds in relation to a Data Subject on request;
    - (v) assistance that it requests following any Data Loss Event; and





## Medicines & Healthcare products Regulatory Agency

- (vi) assistance that it requests relating to a consultation with, or request from, the Information Commissioner's Office or any other regulatory authority.
- (l) The Processor must maintain full, accurate records and information to show it complies with this clause 14. This requirement does not apply where the Processor employs fewer than 250 staff, unless either the Controller determines that the processing:
  - (i) is not occasional;
  - (ii) includes special categories of data as referred to in Article 9(1) of the UK GDPR or Personal Data relating to criminal convictions and offences referred to in Article 10 of the UK GDPR; or
  - (iii) is likely to result in a risk to the rights and freedoms of Data Subjects.
- (m) The Parties shall designate a Data Protection Officer if required by the Data Protection Legislation.
- (n) Before allowing any Subprocessor to process any Personal Data, the Processor must:
  - (i) notify the Controller in writing of the intended Subprocessor and processing;
  - (ii) obtain the written consent of the Controller;
  - (iii) enter into a written contract with the Subprocessor so that this clause 14 applies to the Subprocessor; and
  - (iv) provide the Controller with any information about the Subprocessor that the Controller reasonably requires.
- (o) The Processor remains fully liable for all acts or omissions of any Subprocessor.
- (p) At any time the Buyer can, with 30 Working Days' notice to the Supplier, change this clause 14 to replace it with any applicable standard clauses (between the controller and processor) or similar terms forming part of an applicable certification scheme (which shall apply when incorporated by attachment to the Contract).
- (q) The Parties agree to take account of any non-mandatory guidance issued by the Information Commissioner's Office or any other regulatory authority.

### 14.10 Joint Controllers of Personal Data

In the event that the Parties are Joint Controllers in respect of Personal Data under the Contract, the Parties shall implement paragraphs that are necessary to comply with UK GDPR Article 26 based on the terms set out in **Error! Reference source not found.** of Annex 1 – *Processing Personal Data*.

### 14.11 Independent Controllers of Personal Data

In the event that the Parties are Independent Controllers in respect of Personal Data under the Contract, the terms set out in **Error! Reference source not found.** of Annex 1 – *Processing Personal Data* shall apply to this Contract.

## 15. What you must keep confidential

### 15.1 Each Party must:



## Medicines & Healthcare products Regulatory Agency

- (a) keep all Confidential Information it receives confidential and secure;
  - (b) not disclose, use or exploit the disclosing Party's Confidential Information without the disclosing Party's prior written consent, except for the purposes anticipated under the Contract; and
  - (c) immediately notify the disclosing Party if it suspects unauthorised access, copying, use or disclosure of the Confidential Information.
- 15.2 In spite of clause 15.1, a Party may disclose Confidential Information which it receives from the disclosing Party in any of the following instances:
- (a) where disclosure is required by applicable Law, a regulatory body or a court with the relevant jurisdiction if the recipient Party notifies the disclosing Party of the full circumstances, the affected Confidential Information and extent of the disclosure;
  - (b) if the recipient Party already had the information without obligation of confidentiality before it was disclosed by the disclosing Party;
  - (c) if the information was given to it by a third party without obligation of confidentiality;
  - (d) if the information was in the public domain at the time of the disclosure;
  - (e) if the information was independently developed without access to the disclosing Party's Confidential Information;
  - (f) on a confidential basis, to its auditors or for the purposes of regulatory requirements;
  - (g) on a confidential basis, to its professional advisers on a need-to-know basis; and
  - (h) to the Serious Fraud Office where the recipient Party has reasonable grounds to believe that the disclosing Party is involved in activity that may be a criminal offence under the Bribery Act 2010.
- 15.3 The Supplier may disclose Confidential Information on a confidential basis to Supplier Staff on a need-to-know basis to allow the Supplier to meet its obligations under the Contract. The Supplier shall remain responsible at all times for compliance with the confidentiality obligations set out in this Contract by the persons to whom disclosure has been made.
- 15.4 The Buyer may disclose Confidential Information in any of the following cases:
- (a) on a confidential basis to the employees, agents, consultants and contractors of the Buyer;
  - (b) on a confidential basis to any other Central Government Body, any successor body to a Central Government Body or any company that the Buyer transfers or proposes to transfer all or any part of its business to;
  - (c) if the Buyer (acting reasonably) considers disclosure necessary or appropriate to carry out its public functions;
  - (d) where requested by Parliament; and
  - (e) under clauses 5.7 and 16.



## Medicines & Healthcare products Regulatory Agency

- 15.5 For the purposes of clauses 15.2 to 15.4 references to disclosure on a confidential basis means disclosure under a confidentiality agreement or arrangement including terms as strict as those required in clause 15.
- 15.6 Transparency Information, and Information which is exempt from disclosure by clause 16 is not Confidential Information.
- 15.7 The Supplier must not make any press announcement or publicise the Contract or any part of it in any way, without the prior written consent of the Buyer and must take all reasonable endeavours to ensure that Supplier Staff do not either.

### **16. When you can share information**

- 16.1 The Supplier must tell the Buyer within 48 hours if it receives a Request For Information.
- 16.2 In accordance with a reasonable timetable and in any event within 5 Working Days of a request from the Buyer, the Supplier must give the Buyer full co-operation and information needed so the Buyer can:
- (a) comply with any FOIA request;
  - (b) comply with any Environmental Information Regulations (“**EIR**”) request;
  - (c) if the Contract has a value over the relevant threshold in Part 2 of the Regulations, comply with any of its obligations in relation to publishing Transparency Information.
- 16.3 To the extent that it is allowed and practical to do so, the Buyer will use reasonable endeavours to notify the Supplier of a Request For Information and may talk to the Supplier to help it decide whether to publish information under clause 16. However, the extent, content and format of the disclosure is the Buyer’s decision in its absolute discretion.

### **17. Insurance**

The Supplier shall ensure it has adequate insurance cover for this Contract.

### **18. Invalid parts of the contract**

If any part of the Contract is prohibited by Law or judged by a court to be unlawful, void or unenforceable, it must be read as if it was removed from the Contract as much as required and rendered ineffective as far as possible without affecting the rest of the Contract, whether it’s valid or enforceable.

### **19. No other terms apply**

The provisions incorporated into the Contract are the entire agreement between the Parties. The Contract replaces all previous statements, or agreements whether written or oral. No other provisions apply.

### **20. Other people's rights in the contract**

No third parties may use the Contracts (Rights of Third Parties) Act (“**CRTPA**”) to enforce any term of the Contract unless stated (referring to CRTPA) in the Contract. This does not affect third party rights and remedies that exist independently from CRTPA.



## Medicines & Healthcare products Regulatory Agency

### **21. Circumstances beyond your control**

- 21.1 Any Party affected by a Force Majeure Event is excused from performing its obligations under the Contract while the inability to perform continues, if it both:
- (a) provides written notice to the other Party; and
  - (b) uses all reasonable measures practical to reduce the impact of the Force Majeure Event.
- 21.2 Any failure or delay by the Supplier to perform its obligations under the Contract that is due to a failure or delay by an agent, Subcontractor and/or Supplier Staff will only be considered a Force Majeure Event if that third party is itself prevented from complying with an obligation to the Supplier due to a Force Majeure Event.
- 21.3 Either Party can partially or fully terminate the Contract if the provision of the Deliverables is materially affected by a Force Majeure Event which lasts for 90 days continuously.
- 21.4 Where a Party terminates under clause 21.3:
- (a) each Party must cover its own losses; and
  - (b) clause 11.5(a)(ii) to 11.5(a)(viii) applies.

### **22. Relationships created by the contract**

The Contract does not create a partnership, joint venture or employment relationship. The Supplier must represent themselves accordingly and ensure others do so.

### **23. Giving up contract rights**

A partial or full waiver or relaxation of the terms of the Contract is only valid if it is stated to be a waiver in writing to the other Party.

### **24. Transferring responsibilities**

- 24.1 The Supplier cannot assign, novate or in any other way dispose of the Contract or any part of it without the Buyer's written consent.
- 24.2 The Buyer can assign, novate or transfer its Contract or any part of it to any Crown Body, public or private sector body which performs the functions of the Buyer.
- 24.3 When the Buyer uses its rights under clause 24.2 the Supplier must enter into a novation agreement in the form that the Buyer specifies.
- 24.4 The Supplier can terminate the Contract novated under clause 24.2 to a private sector body that is experiencing an Insolvency Event.
- 24.5 The Supplier remains responsible for all acts and omissions of the Supplier Staff as if they were its own.

### **25. Supply Chain**

- 25.1 The Supplier cannot sub-contract the Contract or any part of it without the Buyer's prior written consent. The Supplier shall provide the Buyer with the name of any Subcontractor the Supplier proposes to engage for the purposes of the Contract. The decision of the Buyer to consent or not will not be unreasonably withheld or delayed. If the Buyer does not communicate a decision to the Supplier within 10 Working Days of the request for consent then its consent will be deemed to have



## Medicines & Healthcare products Regulatory Agency

been given. The Buyer may reasonably withhold its consent to the appointment of a Subcontractor if it considers that:

- (a) the appointment of a proposed Subcontractor may prejudice the provision of the Deliverables or may be contrary to its interests;
- (b) the proposed Subcontractor is unreliable and/or has not provided reliable goods and or reasonable services to its other customers; and/or
- (c) the proposed Subcontractor employs unfit persons.

25.2 If the Buyer asks the Supplier for details about Subcontractors, the Supplier must provide details of all such Subcontractors at all levels of the supply chain including:

- (a) their name;
- (b) the scope of their appointment; and
- (c) the duration of their appointment.

25.3 The Supplier must exercise due skill and care when it selects and appoints Subcontractors.

25.4 The Supplier will ensure that all Sub-Contracts in the Supplier's supply chain entered into after the Start Date wholly or substantially for the purpose of performing or contributing to the performance of the whole or any part of this Contract contain provisions that:

- (a) allow the Supplier to terminate the Sub-Contract if the Subcontractor fails to comply with its obligations in respect of environmental, social, equality or employment Law;
- (b) require the Supplier to pay all Subcontractors in full, within 30 days of receiving a valid, undisputed invoice; and
- (c) allow the Buyer to publish the details of the late payment or non-payment if this 30-day limit is exceeded.

25.5 The Supplier will take reasonable endeavours to ensure that all Sub-Contracts in the Supplier's supply chain entered into before the Start Date but made wholly or substantially for the purpose of performing or contributing to the performance of the whole or any part of this Contract contain provisions that:

- (a) allow the Supplier to terminate the Sub-Contract if the Subcontractor fails to comply with its obligations in respect of environmental, social, equality or employment Law;
- (b) require the Supplier to pay all Subcontractors in full, within 30 days of receiving a valid, undisputed invoice; and
- (c) allow the Buyer to publish the details of the late payment or non-payment if this 30-day limit is exceeded.

25.6 At the Buyer's request, the Supplier must terminate any Sub-Contracts in any of the following events:

- (a) there is a change of control within the meaning of Section 450 of the Corporation Tax Act 2010 of a Subcontractor which isn't pre-approved by the Buyer in writing;



## Medicines & Healthcare products Regulatory Agency

- (b) the acts or omissions of the Subcontractor have caused or materially contributed to a right of termination under Clause 11.4;
- (c) a Subcontractor or its Affiliates embarrasses or brings into disrepute or diminishes the public trust in the Buyer;
- (d) the Subcontractor fails to comply with its obligations in respect of environmental, social, equality or employment Law; and/or
- (e) the Buyer has found grounds to exclude the Subcontractor in accordance with Regulation 57 of the Regulations.

25.7 The Supplier is responsible for all acts and omissions of its Subcontractors and those employed or engaged by them as if they were its own.

### **26. Changing the contract**

Either Party can request a variation to the Contract which is only effective if agreed in writing and signed by both Parties. The Buyer is not required to accept a variation request made by the Supplier.

### **27. How to communicate about the contract**

- 27.1 All notices under the Contract must be in writing and are considered effective on the Working Day of Delivery as long as they're delivered before 5:00pm on a Working Day. Otherwise the notice is effective on the next Working Day. An email is effective at 9am on the first Working Day after sending unless an error message is received.
- 27.2 Notices to the Buyer or Supplier must be sent to their address or email address in the Order Form.
- 27.3 This clause does not apply to the service of legal proceedings or any documents in any legal action, arbitration or dispute resolution.

### **28. Dealing with claims**

- 28.1 If the Buyer becomes aware of any Claim, the Buyer must:
- (a) notify the Supplier as soon as reasonably practical becoming aware of a Claim;
  - (b) at the Supplier's cost, allow the Supplier to conduct all negotiations and proceedings to do with a Claim;
  - (c) at the Supplier's cost, give the Supplier reasonable assistance with the Claim if requested; and
  - (d) not make admissions about the Claim without the prior written consent of the Supplier which cannot be unreasonably withheld or delayed.
- 28.2 The Supplier must:
- (a) consider and defend the Claim diligently and in a way that does not damage the Buyer's reputation; and
  - (b) not settle or compromise any Claim without the Buyer's prior written consent which it must not unreasonably withhold or delay.

### **29. Preventing fraud, bribery and corruption**

- 29.1 The Supplier shall not:



## Medicines & Healthcare products Regulatory Agency

- (a) commit any criminal offence referred to in 57(1) and 57(2) of the Regulations; or
  - (b) offer, give, or agree to give anything, to any person (whether working for or engaged by the Buyer or any other public body) an inducement or reward for doing, refraining from doing, or for having done or refrained from doing, any act in relation to the obtaining or execution of the Contract or any other public function or for showing or refraining from showing favour or disfavour to any person in relation to the Contract or any other public function.
- 29.2 The Supplier shall take all reasonable endeavours (including creating, maintaining and enforcing adequate policies, procedures and records), in accordance with Good Industry Practice, to prevent any matters referred to in clause 29.1 and any fraud by the Supplier Staff and the Supplier (including its shareholders, members and directors) in connection with the Contract and shall notify the Buyer immediately if it has reason to suspect that any such matters have occurred or is occurring or is likely to occur.
- 29.3 If the Supplier notifies the Buyer as required by clause 29.2, the Supplier must respond promptly to their further enquiries, co-operate with any investigation and allow the Audit of any books, records and relevant documentation.
- 29.4 If the Supplier or the Supplier Staff engages in conduct prohibited by clause 29.1 or commits fraud in relation to the Contract or any other contract with the Crown (including the Buyer) the Buyer may:
  - (a) require the Supplier to remove any Supplier Staff from providing the Deliverables if their acts or omissions have caused the default; and
  - (b) immediately terminate the Contract.
- 30. Equality, diversity and human rights**
- 30.1 The Supplier must follow all applicable employment and equality Law when they perform their obligations under the Contract, including:
  - (a) protections against discrimination on the grounds of race, sex, gender reassignment, religion or belief, disability, sexual orientation, pregnancy, maternity, age or otherwise; and
  - (b) any other requirements and instructions which the Buyer reasonably imposes related to equality Law.
- 30.2 The Supplier must use all reasonable endeavours, and inform the Buyer of the steps taken, to prevent anything that is considered to be unlawful discrimination by any court or tribunal, or the Equality and Human Rights Commission (or any successor organisation) when working on the Contract.
- 31. Health and safety**
- 31.1 The Supplier must perform its obligations meeting the requirements of:
  - (a) all applicable Law regarding health and safety; and
  - (b) the Buyer's current health and safety policy while at the Buyer's premises, as provided to the Supplier.





## Medicines & Healthcare products Regulatory Agency

- 31.2 The Supplier and the Buyer must as soon as possible notify the other of any health and safety incidents or material hazards they're aware of at the Buyer premises that relate to the performance of the Contract.

### **32. Environment and sustainability**

- 32.1 In performing its obligations under the Contract, the Supplier shall, to the reasonable satisfaction of the Buyer:
- (a) meet, in all material respects, the requirements of all applicable Laws regarding the environment; and
  - (b) comply with its obligations under the Buyer's current environmental policy, which the Buyer must provide.
- 32.2 The Supplier must ensure that Supplier Staff are aware of the Buyer's environmental policy.

### **33. Tax**

- 33.1 The Supplier must not breach any tax or social security obligations and must enter into a binding agreement to pay any late contributions due, including where applicable, any interest or any fines. The Buyer cannot terminate the Contract where the Supplier has not paid a minor tax or social security contribution.
- 33.2 Where the Supplier or any Supplier Staff are liable to be taxed or to pay National Insurance contributions in the UK relating to payment received under the Contract, the Supplier must both:
- (a) comply with the Income Tax (Earnings and Pensions) Act 2003 and all other statutes and regulations relating to income tax, the Social Security Contributions and Benefits Act 1992 (including IR35) and National Insurance contributions; and
  - (b) indemnify the Buyer against any Income Tax, National Insurance and social security contributions and any other liability, deduction, contribution, assessment or claim arising from or made during or after the Term in connection with the provision of the Deliverables by the Supplier or any of the Supplier Staff.
- 33.3 If any of the Supplier Staff are Workers who receive payment relating to the Deliverables, then the Supplier must ensure that its contract with the Worker contains requirements that:
- (a) the Buyer may, at any time during the term of the Contract, request that the Worker provides information which demonstrates they comply with clause 33.2, or why those requirements do not apply, the Buyer can specify the information the Worker must provide and the deadline for responding;
  - (b) the Worker's contract may be terminated at the Buyer's request if the Worker fails to provide the information requested by the Buyer within the time specified by the Buyer;
  - (c) the Worker's contract may be terminated at the Buyer's request if the Worker provides information which the Buyer considers isn't good enough to demonstrate how it complies with clause 33.2 or confirms that the Worker is not complying with those requirements; and





## Medicines & Healthcare products Regulatory Agency

- (d) the Buyer may supply any information they receive from the Worker to HMRC for revenue collection and management.

### **34. Conflict of interest**

- 34.1 The Supplier must take action to ensure that neither the Supplier nor the Supplier Staff are placed in the position of an actual, potential or perceived Conflict of Interest.
- 34.2 The Supplier must promptly notify and provide details to the Buyer if an actual, potential or perceived Conflict of Interest happens or is expected to happen.
- 34.3 The Buyer will consider whether there are any appropriate measures that can be put in place to remedy an actual, perceived or potential Conflict of Interest. If, in the reasonable opinion of the Buyer, such measures do not or will not resolve an actual or potential conflict of interest, the Buyer may terminate the Contract immediately by giving notice in writing to the Supplier where there is or may be an actual or potential Conflict of Interest and clauses 11.5(a)(ii) to 11.5(a)(viii) shall apply.

### **35. Reporting a breach of the contract**

- 35.1 As soon as it is aware of it the Supplier and Supplier Staff must report to the Buyer any actual or suspected breach of Law, clause 13.1, or clauses 28 to 34.
- 35.2 The Supplier must not retaliate against any of the Supplier Staff who in good faith reports a breach listed in clause 35.1 to the Buyer or a Prescribed Person.

### **36. Further Assurances**

Each Party will, at the request and cost of the other Party, do all things which may be reasonably necessary to give effect to the meaning of this Contract.

### **37. Resolving disputes**

- 37.1 If there is a dispute between the Parties, their senior representatives who have authority to settle the dispute will, within 28 days of a written request from the other Party, meet in good faith to resolve the dispute by commercial negotiation.
- 37.2 If the dispute is not resolved at that meeting, the Parties can attempt to settle it by mediation using the Centre for Effective Dispute Resolution (“CEDR”) Model Mediation Procedure current at the time of the dispute. If the Parties cannot agree on a mediator, the mediator will be nominated by CEDR. If either Party does not wish to use, or continue to use mediation, or mediation does not resolve the dispute, the dispute must be resolved using clauses 37.3 to 37.5.
- 37.3 Unless the Buyer refers the dispute to arbitration using clause 37.4, the Parties irrevocably agree that the courts of England and Wales have the exclusive jurisdiction to:
  - (a) determine the dispute;
  - (b) grant interim remedies; and
  - (c) grant any other provisional or protective relief.
- 37.4 The Supplier agrees that the Buyer has the exclusive right to refer any dispute to be finally resolved by arbitration under the London Court of International Arbitration Rules current at the time of the dispute. There will be only one arbitrator. The seat or legal place of the arbitration will be London and the proceedings will be in English.



## Medicines & Healthcare products Regulatory Agency

37.5 The Buyer has the right to refer a dispute to arbitration even if the Supplier has started or has attempted to start court proceedings under clause 37.3, unless the Buyer has agreed to the court proceedings or participated in them. Even if court proceedings have started, the Parties must do everything necessary to ensure that the court proceedings are stayed in favour of any arbitration proceedings if they are started under clause 37.4.

37.6 The Supplier cannot suspend the performance of the Contract during any dispute.

### **38. Which law applies**

This Contract and any issues or disputes arising out of, or connected to it, are governed by English law.